

HUMANA INC
Form 10-Q
July 30, 2014
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

x **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended June 30, 2014

OR

.. **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from _____ to _____

Commission file number 1-5975

HUMANA INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

61-0647538
(I.R.S. Employer
Identification Number)

500 West Main Street
Louisville, Kentucky 40202
(Address of principal executive offices, including zip code)

(502) 580-1000
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No

Indicate the number of shares outstanding of each of the issuer's classes of common stock as of the latest practicable date.

Class of Common Stock

Outstanding at

\$0.16 $\frac{2}{3}$ par value

June 30, 2014
154,254,938 shares

Table of Contents

Humana Inc.

FORM 10-Q

JUNE 30, 2014

INDEX

	Page
Part I: Financial Information	
Item 1. Financial Statements (Unaudited)	
<u>Condensed Consolidated Balance Sheets at June 30, 2014 and December 31, 2013</u>	3
<u>Condensed Consolidated Statements of Income for the three and six months ended June 30, 2014 and 2013</u>	4
<u>Condensed Consolidated Statements of Comprehensive Income for the three and six months ended June 30, 2014 and 2013</u>	5
<u>Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2014 and 2013</u>	6
<u>Notes to Condensed Consolidated Financial Statements</u>	7
Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	29
Item 3. <u>Quantitative and Qualitative Disclosures about Market Risk</u>	52
Item 4. <u>Controls and Procedures</u>	52
Part II: Other Information	
Item 1. <u>Legal Proceedings</u>	53
Item 1A. <u>Risk Factors</u>	53
Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	54
Item 3. <u>Defaults Upon Senior Securities</u>	55
Item 4. <u>Mine Safety Disclosures</u>	55
Item 5. <u>Other Information</u>	55
Item 6. <u>Exhibits</u>	55
<u>Signatures</u>	56
Certifications	

Table of Contents**Humana Inc.****CONDENSED CONSOLIDATED BALANCE SHEETS****(Unaudited)**

	June 30, 2014	December 31, 2013
	(in millions, except share amounts)	
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 1,593	\$ 1,138
Investment securities	7,565	8,090
Receivables, less allowance for doubtful accounts of \$121 in 2014 and \$118 in 2013:	2,074	950
Other current assets	2,854	2,122
Total current assets	14,086	12,300
Property and equipment, net	1,289	1,218
Long-term investment securities	1,895	1,710
Goodwill	3,696	3,733
Other long-term assets	2,155	1,774
Total assets	\$ 23,121	\$ 20,735
LIABILITIES AND STOCKHOLDERS EQUITY		
Current liabilities:		
Benefits payable	\$ 4,778	\$ 3,893
Trade accounts payable and accrued expenses	2,559	1,821
Book overdraft	294	403
Unearned revenues	249	206
Total current liabilities	7,880	6,323
Long-term debt	2,595	2,600
Future policy benefits payable	2,286	2,207
Other long-term liabilities	360	289
Total liabilities	13,121	11,419
Commitments and contingencies		
Stockholders' equity:		
Preferred stock, \$1 par; 10,000,000 shares authorized; none issued		
Common stock, \$0.16 2/3 par; 300,000,000 shares authorized; 197,795,664 shares issued at June 30, 2014 and 196,275,506 shares issued at December 31, 2013	33	33

Edgar Filing: HUMANA INC - Form 10-Q

Capital in excess of par value	2,376	2,267
Retained earnings	9,567	8,942
Accumulated other comprehensive income	260	158
Treasury stock, at cost, 43,540,726 shares at June 30, 2014 and 42,245,097 shares at December 31, 2013	(2,236)	(2,084)
Total stockholders' equity	10,000	9,316
Total liabilities and stockholders' equity	\$ 23,121	\$ 20,735

See accompanying notes to condensed consolidated financial statements.

Table of Contents**Humana Inc.****CONDENSED CONSOLIDATED STATEMENTS OF INCOME****(Unaudited)**

	Three months ended June 30,		Six months ended June 30,	
	2014	2013	2014	2013
	(in millions, except per share results)			
Revenues:				
Premiums	\$ 11,584	\$ 9,701	\$ 22,667	\$ 19,569
Services	546	528	1,084	1,053
Investment income	92	92	183	185
Total revenues	12,222	10,321	23,934	20,807
Operating expenses:				
Benefits	9,627	8,091	18,751	16,286
Operating costs	1,835	1,461	3,620	2,907
Depreciation and amortization	79	80	161	160
Total operating expenses	11,541	9,632	22,532	19,353
Income from operations	681	689	1,402	1,454
Interest expense	35	35	70	70
Income before income taxes	646	654	1,332	1,384
Provision for income taxes	302	234	620	491
Net income	\$ 344	\$ 420	\$ 712	\$ 893
Basic earnings per common share	\$ 2.22	\$ 2.66	\$ 4.59	\$ 5.64
Diluted earnings per common share	\$ 2.19	\$ 2.63	\$ 4.54	\$ 5.58
Dividends per common share	\$ 0.28	\$ 0.27	\$ 0.55	\$ 0.53

See accompanying notes to condensed consolidated financial statements.

Table of Contents**Humana Inc.****CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME****(Unaudited)**

	Three months ended		Six months ended	
	June 30,		June 30,	
	2014	2013	2014	2013
	(in millions)			
Net income	\$ 344	\$ 420	\$ 712	\$ 893
Other comprehensive income (loss):				
Change in gross unrealized investment gains/losses	56	(183)	164	(270)
Effect of income taxes	(21)	67	(60)	99
Total change in unrealized investment gains/losses, net of tax	35	(116)	104	(171)
Reclassification adjustment for net realized gains included in investment income	(2)	(6)	(3)	(10)
Effect of income taxes	1	2	1	4
Total reclassification adjustment, net of tax	(1)	(4)	(2)	(6)
Other comprehensive income (loss), net of tax	34	(120)	102	(177)
Comprehensive income	\$ 378	\$ 300	\$ 814	\$ 716

See accompanying notes to condensed consolidated financial statements.

Table of Contents**Humana Inc.****CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS****(Unaudited)**

	For the six months ended June 30,	
	2014	2013
	(in millions)	
Cash flows from operating activities		
Net income	\$ 712	\$ 893
Adjustments to reconcile net income to net cash provided by operating activities:		
Net realized capital gains	(3)	(10)
Stock-based compensation	55	51
Depreciation and amortization	213	206
Benefit for deferred income taxes	(39)	(8)
Changes in operating assets and liabilities, net of effect of businesses acquired:		
Receivables	(1,137)	(860)
Other assets	(914)	(108)
Benefits payable	885	378
Other liabilities	641	52
Unearned revenues	42	(37)
Other, net	16	28
Net cash provided by operating activities	471	585
Cash flows from investing activities		
Acquisitions, net of cash acquired	(3)	(12)
Proceeds from sale of business	72	33
Purchases of property and equipment	(216)	(187)
Purchases of investment securities	(968)	(1,385)
Maturities of investment securities	512	549
Proceeds from sales of investment securities	1,007	854
Net cash provided by (used in) investing activities	404	(148)
Cash flows from financing activities		
Receipts (withdrawals) from contract deposits, net	(127)	132
Change in book overdraft	(109)	(78)
Common stock repurchases	(152)	(231)
Dividends paid	(86)	(83)
Excess tax benefit from stock-based compensation	9	
Proceeds from stock option exercises and other	45	36
Net cash used in financing activities	(420)	(224)

Increase in cash and cash equivalents	455	213
Cash and cash equivalents at beginning of period	1,138	1,306
Cash and cash equivalents at end of period	\$ 1,593	\$ 1,519
Supplemental cash flow disclosures:		
Interest payments	\$ 73	\$ 72
Income tax payments, net	\$ 601	\$ 511

See accompanying notes to condensed consolidated financial statements.

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Unaudited

1. BASIS OF PRESENTATION

The accompanying condensed consolidated financial statements are presented in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the disclosures normally required by accounting principles generally accepted in the United States of America, or GAAP, or those normally made in an Annual Report on Form 10-K. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. For further information, the reader of this Form 10-Q should refer to our Form 10-K for the year ended December 31, 2013, that was filed with the Securities and Exchange Commission, or the SEC, on February 19, 2014. We refer to the Form 10-K as the 2013 Form 10-K in this document. References throughout this document to we, us, our, Company, and Humana mean Humana Inc. and its subsidiaries.

The preparation of our condensed consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The areas involving the most significant use of estimates are the estimation of benefits payable, the impact of risk sharing provisions related to our Medicare contracts, the valuation and related impairment recognition of investment securities, and the valuation and related impairment recognition of long-lived assets, including goodwill. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates. Refer to Note 2 to the consolidated financial statements included in our 2013 Form 10-K for information on accounting policies that the Company considers in preparing its consolidated financial statements.

The financial information has been prepared in accordance with our customary accounting practices and has not been audited. In our opinion, the information presented reflects all adjustments necessary for a fair statement of interim results. All such adjustments are of a normal and recurring nature.

Business Segment Reclassifications

On January 1, 2014, we reclassified certain of our businesses from our Healthcare Services segment to our Employer Group segment to correspond with internal management reporting changes. Our reportable segments remain the same and prior period segment financial information has been recast to conform to the 2014 presentation. See Note 12 for segment financial information.

Health Care Reform

The Patient Protection and Affordable Care Act and The Health Care and Education Reconciliation Act of 2010 (which we collectively refer to as the Health Care Reform Law) enacted significant reforms to various aspects of the U.S. health insurance industry. Certain of these reforms became effective January 1, 2014, including an annual insurance industry premium-based fee and the establishment of federally-facilitated or state-based exchanges coupled with three premium stabilization programs, as described more fully below.

The Health Care Reform Law imposes an annual premium-based fee on health insurers for each calendar year beginning on or after January 1, 2014 which is not deductible for tax purposes. We are required to estimate a liability for the health insurer fee and record it in full once qualifying insurance coverage is provided in the applicable calendar year in which the fee is payable with a corresponding deferred cost that is amortized ratably to expense over the same calendar year. In September 2014, we expect to pay the federal government approximately \$560 million for the annual health insurance industry fee attributed to calendar year 2014, in accordance with the Health Care Reform Law. We have recorded a liability for this fee in other current liabilities with a corresponding deferred cost in other current assets in our condensed consolidated financial statements. Amortization of the deferred cost resulted in operating cost expense of approximately \$280 million for the six months ended June 30, 2014 and a remaining deferred cost asset balance of approximately \$280 million at June 30, 2014. No such amounts were recorded at December 31, 2013 as the qualifying insurance coverage was not provided until January 1, 2014.

Table of Contents**Humana Inc.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****Unaudited**

The Health Care Reform Law also establishes risk spreading premium stabilization programs effective January 1, 2014. The risk spreading programs are applicable to certain of our commercial medical insurance products. In the aggregate, our commercial medical insurance products represented approximately 17.2% of our total premiums and services revenue for the six months ended June 30, 2014. These programs, commonly referred to as the 3Rs, include a permanent risk adjustment program, a transitional reinsurance program, and a temporary risk corridors program designed to more evenly spread the financial risk borne by issuers and to mitigate the risk that issuers would have mispriced products. The transitional reinsurance and temporary risk corridors programs are for years 2014 through 2016, with potential for additional reinsurance recoveries through 2018 to the extent funds are available. Policies issued prior to March 23, 2010 are considered grandfathered policies and are exempt from the 3Rs. Certain states have allowed non-grandfathered policies issued prior to January 1, 2014 to extend the date of required transition to policies compliant with the Health Care Reform Law to as late as 2017. Accordingly, such policies are exempt from the 3Rs until they transition to policies compliant with the Health Care Reform Law.

The permanent risk adjustment program adjusts the premiums that commercial individual and small group health insurance issuers receive based on the demographic factors and health status of each member as derived from current year medical diagnosis as reported throughout the year. This program transfers funds from lower risk plans to higher risk plans within similar plans in the same state. The risk adjustment program is applicable to commercial individual and small group health plans (except certain exempt and grandfathered plans as discussed above) operating both inside and outside of the health insurance exchanges established under the Health Care Reform Law. Under the risk adjustment program, a risk score is assigned to each covered member to determine an average risk score at the individual and small group level by legal entity in a particular market in a state. Additionally, an average risk score is determined for the entire subject population for each market in each state. Settlements are determined on a net basis by legal entity and state. Each health insurance issuer's average risk score is compared to the state's average risk score. Plans with an average risk score below the state average will pay into a pool and health insurance issuers with an average risk score that is greater than the state average risk score will receive money from that pool. We generally rely on providers, including certain network providers who are our employees, to appropriately document all medical data, including the diagnosis codes submitted with claims, as the basis for our risk scores under the program. Our estimate of amounts receivable and/or payable under the risk adjustment program is based on our estimate of both our own and the state average risk scores. Assumptions used in these estimates include but are not limited to geographic considerations including our historical experience in markets we have participated in over a long period of time, member demographics including age and gender for our members and other health insurance issuers, our pricing model, sales data for each metal tier (different metal tiers yield different risk scores), the mix of previously underwritten membership as compared to new members in plans compliant with the Health Care Reform Law, published third party studies, and other publicly available data including regulatory plan filings. We expect to refine our estimates as new information becomes available, including additional data released by the Department of Health and Human Services, or HHS, regarding estimates of state average risk scores. Risk adjustment will be subject to audit by HHS beginning in 2014, however, there will be no payments associated with these audits in 2014 or 2015, the first two years of the program.

The temporary risk corridor program applies to individual and small group Qualified Health Plans (or substantially equivalent plans), or QHPs, as defined by HHS, operating both inside and outside of the exchanges. Accordingly, plans subject to risk adjustment that are not QHPs, including our small group health plans, will not be subject to the risk corridor program. The risk corridor provisions limit issuer gains and losses by comparing allowable medical costs to a target amount, each defined/prescribed by HHS, and sharing the risk for allowable costs with the federal government. Allowable medical costs are adjusted for risk adjustment settlements, transitional reinsurance recoveries, and cost sharing reductions received from HHS. Variances from the target exceeding certain thresholds may result in HHS making additional payments to us or require us to refund HHS a portion of the premiums we received. While risk corridor payments from HHS were expected to be limited to the extent of the risk corridor collections received by HHS over the duration of the program, on May 16, 2014, HHS released clarifying guidance. This guidance indicated that risk corridor collections are expected to be sufficient to make all risk corridor payments, however, in the event of a shortfall, HHS will find other sources of funding for the risk corridors payments, subject to the availability of appropriations.

We estimate and recognize adjustments to premiums revenue for the risk adjustment and risk corridor provisions by projecting our ultimate premium for the calendar year separately for individual and group plans by state and legal entity. Estimated calendar year settlement amounts are recognized ratably during the year and are revised each period to reflect current

Table of Contents**Humana Inc.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****Unaudited**

experience, including changes in risk scores derived from medical diagnoses submitted by providers. We record receivables or payables at the individual or group level within each state and legal entity and classify the amounts as current or long-term in the condensed consolidated balance sheets based on the timing of expected settlement.

The transitional reinsurance program requires us to make reinsurance contributions for calendar years 2014 through 2016 to a state or HHS established reinsurance entity based on a national contribution rate per covered member as determined by HHS. While all commercial medical plans, including self-funded plans, are required to fund the reinsurance entity, only fully-insured non-grandfathered plans compliant with the Health Care Reform Law in the individual commercial market will be eligible for recoveries if individual claims exceed a specified threshold. Accordingly, we account for transitional reinsurance contributions associated with all commercial medical health plans other than these non-grandfathered individual plans as an assessment in operating costs in our condensed consolidated statements of income. We account for contributions made by individual commercial plans compliant with the Health Care Reform Law, which are subject to recoveries, as ceded premiums (a reduction of premiums) and similarly we account for any recoveries as ceded benefits (a reduction of benefits expense) in our condensed consolidated statements of income. For the six months ended June 30, 2014, we recorded operating costs of \$50 million associated with transitional reinsurance contributions for plans other than non-grandfathered individual commercial plans. In addition, for our non-grandfathered individual commercial plans we recorded ceded premiums of \$13 million and recorded ceded benefits of \$153 million in our condensed consolidated statements of income for the six months ended June 30, 2014. No such amounts were recorded in 2013 as the program was not effective until January 1, 2014.

The accompanying condensed consolidated balance sheets include the following amounts associated with the 3Rs at June 30, 2014. No such amounts were recorded in our condensed consolidated balance sheet at December 31, 2013 as the programs were not effective until January 1, 2014. The risk adjustment, risk corridor, and reinsurance recoverable settlements include amounts classified as long-term because settlement associated with the 2014 provision exceeds 12 months at June 30, 2014.

	June 30, 2014		
	Risk Adjustment/Risk		
	Corridor Settlement	Reinsurance Contribution	Reinsurance Recoverables
	(in millions)		
Trade accounts payable and accrued expenses	\$	\$ (63)	\$
Other long-term assets	102		153
Other long-term liabilities	(15)		

Net long-term asset	\$ 87	\$	\$	153
Total net asset (liability)	\$ 87	\$	(63)	\$ 153

We are required to remit payment for our per member reinsurance contribution in January of the year following the benefit year, or January 2015 for the 2014 benefit year. Risk adjustment calculations will be completed and HHS will notify us of recoveries due or payments owed to/from us under the risk adjustment and reinsurance programs by June 30 of the year following the benefit year. Payments due to HHS under the risk adjustment program must be remitted within 30 days of notification and will be collected prior to the distribution of recoveries by HHS. Following this notification, risk corridor calculations are then due by July 31 of the year following the benefit year. Payment and recovery amounts will be settled with HHS annually in the second half of the year following the benefit year. Accordingly, for the 2014 benefit year, we expect to receive recoveries and/or pay amounts due under these programs in the second half of 2015.

In addition to the provisions discussed above, beginning in 2014, HHS pays us a portion of the health care costs for low-income individual members for which we assume no risk in accordance with the Health Care Reform Law. We account for these subsidies as a deposit in our consolidated balance sheets and as a financing activity in our consolidated statements of cash flows. We do not recognize premiums revenue or benefits expense for these subsidies. Receipt and payment activity is accumulated at the state and legal entity level and recorded in our consolidated balance sheets in other current assets or trade accounts payable and accrued expenses depending on the state and legal entity balance at the

Table of Contents**Humana Inc.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****Unaudited**

end of the reporting period. We will be notified of final settlement amounts by June 30 of the year following the benefit year. Receipts from HHS associated with these cost sharing subsidies for which we do not assume risk were \$24 million higher than claims payments for the six months ended June 30, 2014.

2. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

In April 2014, the Financial Accounting Standards Board, or FASB, issued new guidance related to discontinued operations which changes the criteria for determining which disposals can be presented as discontinued operations and modifies related disclosure requirements. The new guidance is effective for us beginning with annual and interim periods in 2015 with early adoption permitted under certain circumstances. Based upon existing facts and circumstances, the adoption of the new guidance is not expected to have a material impact on our results of operations, financial condition, or cash flows.

In May 2014, the FASB issued new guidance that amends the accounting for revenue recognition. The amendments are intended to provide a more robust framework for addressing revenue issues, improve comparability of revenue recognition practices, and improve disclosure requirements. Insurance contracts are not in the scope of this new guidance. Accordingly, the new guidance primarily will apply to the recognition of our services revenue, including intersegment revenues associated with our Healthcare Services segment. Services revenue represented less than 5% of our consolidated revenues for the three and six months ended June 30, 2014. The new guidance is effective for us beginning with annual and interim periods in 2017. We are currently evaluating the impact on our results of operations, financial condition, and cash flows.

There are no other recently issued accounting standards that apply to us or that are expected to have a material impact on our results of operations, financial condition, or cash flows.

3. ACQUISITIONS

On September 6, 2013, we acquired American Eldercare Inc., or American Eldercare, the largest provider of nursing home diversion services in the state of Florida, serving frail and elderly individuals in home and community-based settings. American Eldercare complements our core capabilities and strength in serving seniors and disabled individuals with a unique focus on individualized and integrated care, and has contracts to provide Medicaid Long-Term Support Services across the entire state of Florida. The enrollment effective dates for the various regions ranged from August 2013 to March 2014. The allocation of the purchase price resulted in goodwill of \$76 million and other intangible assets of \$75 million. The goodwill was assigned to the Retail segment and is deductible for tax purposes. The other intangible assets, which primarily consist of customer contracts and technology, have a weighted average useful life of 9.3 years. The purchase price allocation is preliminary, subject to completion of valuation analyses, including, for example, refining assumptions used to calculate the fair value of other intangible assets.

The results of operations and financial condition of American Eldercare have been included in our condensed consolidated statements of income and condensed consolidated balance sheets from the acquisition dates. In addition,

during 2014 and 2013, we acquired other health and wellness related businesses which, individually or in the aggregate, have not had, or are not expected to have, a material impact on our results of operations, financial condition, or cash flows. Acquisition-related costs recognized in 2014 and 2013 were not material to our results of operations. The pro forma financial information assuming the acquisitions had occurred as of the beginning of the calendar year prior to the year of acquisition, as well as the revenues and earnings generated during the year of acquisition were not material for disclosure purposes.

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Unaudited

4. INVESTMENT SECURITIES

Investment securities classified as current and long-term were as follows at June 30, 2014 and December 31, 2013, respectively:

	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value
	(in millions)			
<u>June 30, 2014</u>				
U.S. Treasury and other U.S. government corporations and agencies:				
U.S. Treasury and agency obligations	\$ 372	\$ 8	\$ (2)	\$ 378
Mortgage-backed securities	1,490	48	(16)	1,522
Tax-exempt municipal securities	2,998	141	(7)	3,132
Mortgage-backed securities:				
Residential	20	1	(1)	20
Commercial	636	19	(11)	644
Asset-backed securities	41	1		42
Corporate debt securities	3,402	326	(6)	3,722
Total debt securities	\$ 8,959	\$ 544	\$ (43)	\$ 9,460
<u>December 31, 2013</u>				
U.S. Treasury and other U.S. government corporations and agencies:				
U.S. Treasury and agency obligations	\$ 584	\$ 6	\$ (6)	\$ 584
Mortgage-backed securities	1,834	34	(48)	1,820
Tax-exempt municipal securities	2,911	93	(33)	2,971
Mortgage-backed securities:				
Residential	22			22
Commercial	662	20	(9)	673
Asset-backed securities	63	1	(1)	63
Corporate debt securities	3,474	223	(30)	3,667
Total debt securities	\$ 9,550	\$ 377	\$ (127)	\$ 9,800

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Unaudited

Gross unrealized losses and fair values aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position were as follows at June 30, 2014 and December 31, 2013, respectively:

	Less than 12 months		12 months or more		Total	
	Fair Value	Gross Unrealized Losses	Fair Value	Gross Unrealized Losses	Fair Value	Gross Unrealized Losses
	(in millions)					
June 30, 2014						
U.S. Treasury and other U.S. government corporations and agencies:						
U.S. Treasury and agency obligations	\$ 38	\$	\$ 92	\$ (2)	\$ 130	\$ (2)
Mortgage-backed securities	36		505	(16)	541	(16)
Tax-exempt municipal securities	118	(2)	239	(5)	357	(7)
Mortgage-backed securities:						
Residential	4		2	(1)	6	(1)
Commercial	106	(1)	192	(10)	298	(11)
Asset-backed securities			16		16	
Corporate debt securities	30		176	(6)	206	(6)
Total debt securities	\$ 332	\$ (3)	\$ 1,222	\$ (40)	\$ 1,554	\$ (43)
December 31, 2013						
U.S. Treasury and other U.S. government corporations and agencies:						
U.S. Treasury and agency obligations	\$ 231	\$ (6)	\$ 5	\$	\$ 236	\$ (6)
Mortgage-backed securities	1,076	(47)	21	(1)	1,097	(48)
Tax-exempt municipal securities	693	(28)	57	(5)	750	(33)
Mortgage-backed securities:						
Residential	6		1		7	
Commercial	270	(8)	40	(1)	310	(9)
Asset-backed securities	35	(1)			35	(1)
Corporate debt securities	594	(28)	17	(2)	611	(30)
Total debt securities	\$ 2,905	\$ (118)	\$ 141	\$ (9)	\$ 3,046	\$ (127)

Approximately 95% of our debt securities were investment-grade quality, with a weighted average credit rating of AA- by S&P at June 30, 2014. Most of the debt securities that were below investment-grade were rated BB, the higher end of the below investment-grade rating scale. At June 30, 2014, 5% of our tax-exempt municipal securities were pre-refunded, generally with U.S. government and agency securities. Tax-exempt municipal securities that were not pre-refunded were diversified among general obligation bonds of U.S. states and local municipalities as well as special revenue bonds. General obligation bonds, which are backed by the taxing power and full faith of the issuer, accounted for 38% of the tax-exempt municipals that were not pre-refunded in the portfolio. Special revenue bonds, issued by a

Table of Contents**Humana Inc.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****Unaudited**

municipality to finance a specific public works project such as utilities, water and sewer, transportation, or education, and supported by the revenues of that project, accounted for the remaining 62% of these municipals. Our general obligation bonds are diversified across the United States with no individual state exceeding 11%. In addition, 17% of our tax-exempt securities were insured by bond insurers and had an equivalent weighted average S&P credit rating of AA exclusive of the bond insurers' guarantee. Our investment policy limits investments in a single issuer and requires diversification among various asset types.

The recoverability of our non-agency residential and commercial mortgage-backed securities is supported by factors such as seniority, underlying collateral characteristics and credit enhancements. These residential and commercial mortgage-backed securities at June 30, 2014 primarily were composed of senior tranches having high credit support, with over 99% of the collateral consisting of prime loans. The weighted average credit rating of all commercial mortgage-backed securities was AA+ at June 30, 2014.

The percentage of corporate securities associated with the financial services industry was 21% at June 30, 2014 and 23% at December 31, 2013.

All issuers of securities we own that were trading at an unrealized loss at June 30, 2014 remain current on all contractual payments. After taking into account these and other factors previously described, we believe these unrealized losses primarily were caused by an increase in market interest rates and tighter liquidity conditions in the current markets than when the securities were purchased. At June 30, 2014, we did not intend to sell the securities with an unrealized loss position in accumulated other comprehensive income, and it is not likely that we will be required to sell these securities before recovery of their amortized cost basis. As a result, we believe that the securities with an unrealized loss were not other-than-temporarily impaired at June 30, 2014.

The detail of realized gains (losses) related to investment securities and included within investment income was as follows for the three and six months ended June 30, 2014 and 2013:

	Three months ended		Six months ended	
	June 30,		June 30,	
	2014	2013	2014	2013
	(in millions)			
Gross realized gains	\$ 6	\$ 11	\$ 7	\$ 17
Gross realized losses	(4)	(5)	(4)	(7)
Net realized capital gains	\$ 2	\$ 6	\$ 3	\$ 10

There were no material other-than-temporary impairments for the three and six months ended June 30, 2014 or 2013.

The contractual maturities of debt securities available for sale at June 30, 2014, regardless of their balance sheet classification, are shown below. Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.

	Amortized Cost	Fair Value
	(in millions)	
Due within one year	\$ 422	\$ 427
Due after one year through five years	2,144	2,268
Due after five years through ten years	2,264	2,413
Due after ten years	1,942	2,124
Mortgage and asset-backed securities	2,187	2,228
Total debt securities	\$ 8,959	\$ 9,460

Table of Contents**Humana Inc.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****Unaudited****5. FAIR VALUE****Financial Assets**

The following table summarizes our fair value measurements at June 30, 2014 and December 31, 2013, respectively, for financial assets measured at fair value on a recurring basis:

	Fair Value	Fair Value Measurements Using		
		Quoted Prices in Active Markets (Level 1)	Other Observable Inputs (Level 2)	Unobservable Inputs (Level 3)
(in millions)				
June 30, 2014				
Cash equivalents	\$ 1,361	\$ 1,361	\$	\$
Debt securities:				
U.S. Treasury and other U.S. government corporations and agencies:				
U.S. Treasury and agency obligations	378		378	
Mortgage-backed securities	1,522		1,522	
Tax-exempt municipal securities	3,132		3,119	13
Mortgage-backed securities:				
Residential	20		20	
Commercial	644		644	
Asset-backed securities	42		41	1
Corporate debt securities	3,722		3,699	23
Total debt securities	9,460		9,423	37
Total invested assets	\$ 10,821	\$ 1,361	\$ 9,423	\$ 37
December 31, 2013				
Cash equivalents	\$ 876	\$ 876	\$	\$
Debt securities:				
U.S. Treasury and other U.S. government corporations and				

agencies:

U.S. Treasury and agency obligations	584	584		
Mortgage-backed securities	1,820	1,820		
Tax-exempt municipal securities	2,971	2,958		13
Mortgage-backed securities:				
Residential	22	22		
Commercial	673	673		
Asset-backed securities	63	62		1
Corporate debt securities	3,667	3,644		23
Total debt securities	9,800	9,763		37
Total invested assets	\$ 10,676	\$ 876	\$ 9,763	\$ 37

Table of Contents**Humana Inc.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****Unaudited**

There were no material transfers between Level 1 and Level 2 during the three and six months ended June 30, 2014 or June 30, 2013.

Our Level 3 assets had a fair value of \$37 million at June 30, 2014, or less than 0.4% of our total invested assets. During the three and six months ended June 30, 2014 and 2013, the changes in the fair value of the assets measured using significant unobservable inputs (Level 3) were comprised of the following:

	For the three months ended June 30, 2014		Total (in millions)	2013		Total
	Private Placements	Auction Rate Securities		Private Placements	Auction Rate Securities	
Beginning balance at April 1	\$ 24	\$ 13	\$ 37	\$ 25	\$ 13	\$ 38
Total gains or losses:						
Realized in earnings						
Unrealized in other comprehensive income				(2)		(2)
Purchases						
Sales						
Settlements						
Balance at June 30	\$ 24	\$ 13	\$ 37	\$ 23	\$ 13	\$ 36

	For the six months ended June 30, 2014		Total (in millions)	2013		Total
	Private Placements	Auction Rate Securities		Private Placements	Auction Rate Securities	
Beginning balance at January 1	\$ 24	\$ 13	\$ 37	\$ 25	\$ 13	\$ 38
Total gains or losses:						
Realized in earnings						
Unrealized in other comprehensive income				(1)		(1)
Purchases						
Sales						
Settlements				(1)		(1)

Balance at June 30	\$ 24	\$ 13	\$ 37	\$ 23	\$ 13	\$ 36
--------------------	-------	-------	-------	-------	-------	-------

Financial Liabilities

Our long-term debt is recorded at carrying value in our consolidated balance sheets. The carrying value of our long-term debt outstanding was \$2,595 million at June 30, 2014 and \$2,600 million at December 31, 2013. The fair value of our long-term debt was \$2,850 million at June 30, 2014 and \$2,751 million at December 31, 2013. The fair value of our long-term debt is determined based on Level 2 inputs, including quoted market prices for the same or similar debt, or if no quoted market prices are available, on the current prices estimated to be available to us for debt with similar terms and remaining maturities.

Table of Contents**Humana Inc.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****Unaudited*****Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis***

As disclosed in Note 3, the acquisitions of American Eldercare and other health and wellness companies were completed during 2014 and 2013. The values of net tangible assets acquired and the resulting goodwill and other intangible assets were recorded at fair value using Level 3 inputs. The majority of the related tangible assets acquired and liabilities assumed were recorded at their carrying values as of the respective dates of acquisition, as their carrying values approximated their fair values due to their short-term nature. The fair values of goodwill and other intangible assets acquired in these acquisitions were internally estimated primarily based on the income approach. The income approach estimates fair value based on the present value of the cash flows that the assets are expected to generate in the future. We developed internal estimates for the expected cash flows and discount rates used in the present value calculations. Other than assets acquired and liabilities assumed in these acquisitions, there were no material assets or liabilities measured at fair value on a nonrecurring basis during the three and six months ended June 30, 2014 or 2013.

6. MEDICARE PART D

We cover prescription drug benefits in accordance with Medicare Part D under multiple contracts with CMS. The accompanying condensed consolidated balance sheets include the following amounts associated with Medicare Part D at June 30, 2014 and December 31, 2013. The risk corridor settlement includes amounts classified as long-term because settlement associated with the 2014 provision will exceed 12 months at June 30, 2014.

	June 30, 2014		December 31, 2013	
	Risk Corridor Settlement	CMS Subsidies/ Discounts	Risk Corridor Settlement	CMS Subsidies/ Discounts
	(in millions)			
Other current assets	\$ 50	\$ 1,034	\$ 45	\$ 743
Trade accounts payable and accrued expenses	(51)	(199)	(71)	(30)
Net current (liability) asset	(1)	835	(26)	713
Other long-term assets	184			
Other long-term liabilities	(30)			
Net long-term asset	154			
Total net asset (liability)	\$ 153	\$ 835	\$ (26)	\$ 713

7. GOODWILL AND OTHER INTANGIBLE ASSETS

The carrying amount of goodwill for our reportable segments has been retrospectively adjusted to conform to the 2014 presentation as discussed in Note 1. Changes in the carrying amount of goodwill for our reportable segments for the six months ended June 30, 2014 were as follows:

	Retail	Employer Group	Healthcare Services	Other Businesses	Total
	(in millions)				
Balance at January 1, 2014	\$ 1,007	\$ 363	\$ 2,271	\$ 92	\$ 3,733
Acquisitions			3		3
Dispositions			(40)		(40)
Balance at June 30, 2014	\$ 1,007	\$ 363	\$ 2,234	\$ 92	\$ 3,696

Table of Contents**Humana Inc.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****Unaudited**

The following table presents details of our other intangible assets included in other long-term assets in the accompanying condensed consolidated balance sheets at June 30, 2014 and December 31, 2013:

	Weighted Average Life	June 30, 2014			December 31, 2013		
		Cost	Accumulated Amortization	Net	Cost	Accumulated Amortization	Net
(in millions)							
Other intangible assets:							
Customer contracts/ relationships	9.8 yrs	\$ 764	\$ 330	\$ 434	\$ 792	\$ 310	\$ 482
Trade names and technology	13.2 yrs	198	49	149	200	40	160
Provider contracts	16.5 yrs	45	18	27	51	23	28
Noncompetes and other	6.5 yrs	50	31	19	52	29	23
Total other intangible assets	10.4 yrs	\$ 1,057	\$ 428	\$ 629	\$ 1,095	\$ 402	\$ 693

Amortization expense for other intangible assets was approximately \$28 million for the three months ended June 30, 2014 and 2013. For the six months ended June 30, 2014 and 2013, amortization expense for other intangibles was approximately \$56 million. The following table presents our estimate of amortization expense for 2014 and each of the five next succeeding years:

	(in millions)
For the years ending December 31,:	
2014	\$ 111
2015	100
2016	92
2017	85
2018	78
2019	67

Table of Contents**Humana Inc.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****Unaudited****8. EARNINGS PER COMMON SHARE COMPUTATION**

Detail supporting the computation of basic and diluted earnings per common share was as follows for the three and six months ended June 30, 2014 and 2013:

	Three months ended June 30,		Six months ended June 30,	
	2014	2013	2014	2013
	(dollars in millions, except per common share results; number of shares in thousands)			
Net income available for common stockholders	\$ 344	\$ 420	\$ 712	\$ 893
Weighted average outstanding shares of common stock used to compute basic earnings per common share	155,423	157,975	155,257	158,446
Dilutive effect of:				
Employee stock options	227	349	248	367
Restricted stock	1,396	1,197	1,341	1,149
Shares used to compute diluted earnings per common share	157,046	159,521	156,846	159,962
Basic earnings per common share	\$ 2.22	\$ 2.66	\$ 4.59	\$ 5.64
Diluted earnings per common share	\$ 2.19	\$ 2.63	\$ 4.54	\$ 5.58
Number of antidilutive stock options and restricted stock excluded from computation	245	847	609	1,265

9. STOCKHOLDERS EQUITY**Dividends**

The following table provides details of dividend payments in 2013 and 2014 under our Board approved quarterly cash dividend policy:

Record Date	Payment Date	Amount per Share	Total Amount (in millions)
2013 payments			
12/31/2012	1/25/2013	\$ 0.26	\$ 42
3/28/2013	4/26/2013	\$ 0.26	\$ 41
6/28/2013	7/26/2013	\$ 0.27	\$ 42
9/30/2013	10/25/2013	\$ 0.27	\$ 42
2014 payments			
12/31/2013	1/31/2014	\$ 0.27	\$ 42
3/31/2014	4/25/2014	\$ 0.27	\$ 42
6/30/2014	7/25/2014	\$ 0.28	\$ 43

Declaration and payment of future quarterly dividends is at the discretion of the Board and may be adjusted as business needs or market conditions change.

Stock Repurchases

In April 2014, the Board of Directors replaced a previous share repurchase authorization of up to \$1 billion (of which \$569 million remained unused) with a new authorization for repurchases of up to \$1 billion of our common shares exclusive of shares repurchased in connection with employee stock plans, expiring on June 30, 2016. Under the new share repurchase authorization, shares may be purchased from time to time at prevailing prices in the open market, by

Table of Contents**Humana Inc.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****Unaudited**

block purchases, or in privately-negotiated transactions, subject to certain regulatory restrictions on volume, pricing, and timing. During the six months ended June 30, 2014, we repurchased 0.1 million shares in open market transactions for \$11 million at an average price of \$113.44 under a previous share repurchase authorization and we repurchased 0.81 million shares in open market transactions for \$101 million at an average price of \$125.04 under the current authorization. During the six months ended June 30, 2013, we repurchased 2.83 million shares in open market transactions for \$211 million at an average price of \$74.67 under previous share repurchase authorizations. As of July 30, 2014, the remaining authorized amount under the new authorization totaled \$899 million.

In connection with employee stock plans, we acquired 0.4 million common shares for \$40 million and 0.2 million common shares for \$20 million during the six months ended June 30, 2014 and 2013, respectively.

Accumulated Other Comprehensive Income

Accumulated other comprehensive income included net unrealized gains on our investment securities of \$317 million at June 30, 2014 and \$158 million at December 31, 2013. In addition, accumulated other comprehensive income included \$57 million at June 30, 2014 for an additional liability that would exist on our closed block of long-term care insurance policies if unrealized gains on the sale of the investments backing such products had been realized and the proceeds reinvested at then current yields. There was no such additional liability at December 31, 2013. Refer to Note 17 to the consolidated financial statements in our 2013 10-K for further discussion of our long-term care insurance policies.

10. INCOME TAXES

The effective income tax rate was 46.7% for the three months ended June 30, 2014, compared to 35.7% for the three months ended June 30, 2013. For the six months ended June 30, 2014 the effective tax rate was 46.5%, compared to 35.5% for the six months ended June 30, 2013. The non-deductible nature of the health insurance industry fee levied on the industry beginning in 2014 as mandated by the Health Care Reform Law increased our effective tax rate by approximately 9 percentage points for the six months ended June 30, 2014. In addition, the effective tax for the three and six months ended June 30, 2013 includes the beneficial effect of a change in our estimated tax liability associated with limitations on the deductibility of annual compensation in excess of \$500,000 per employee as mandated by the Health Care Reform Law.

11. GUARANTEES AND CONTINGENCIES***Government Contracts***

Our Medicare products, which accounted for approximately 74% of our total premiums and services revenue for the six months ended June 30, 2014, primarily consisted of products covered under the Medicare Advantage and Medicare Part D Prescription Drug Plan contracts with the federal government. These contracts are renewed generally for a calendar year term unless CMS notifies us of its decision not to renew by May 1 of the calendar year in which

the contract would end, or we notify CMS of our decision not to renew by the first Monday in June of the calendar year in which the contract would end. All material contracts between Humana and CMS relating to our Medicare products have been renewed for 2015. However, our offerings of products under those contracts are subject to approval by CMS, which we expect in the fall of 2014.

CMS uses a risk-adjustment model which apportions premiums paid to Medicare Advantage plans according to health severity of covered members. The risk-adjustment model pays more for enrollees with predictably higher costs. Under this model, rates paid to Medicare Advantage plans are based on actuarially determined bids, which include a process whereby our prospective payments are based on a comparison of our beneficiaries' risk scores, derived from medical diagnoses, to those enrolled in the government's original Medicare program. Under the risk-adjustment methodology, all Medicare Advantage plans must collect and submit the necessary diagnosis code information from hospital inpatient, hospital outpatient, and physician providers to CMS within prescribed deadlines. The CMS risk-adjustment model uses the diagnosis data to calculate the risk-adjusted premium payment to Medicare Advantage plans, which CMS adjusts for coding pattern differences between the health plans and the government fee-for-service program. We generally rely on providers, including certain providers in our network who are our employees, to code their claim submissions with appropriate diagnoses, which we send to CMS as the basis for our payment received from CMS under

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Unaudited

the actuarial risk-adjustment model. We also rely on these providers to document appropriately all medical data, including the diagnosis data submitted with claims. In addition, we conduct medical record reviews as part of our data and payment accuracy compliance efforts, to more accurately reflect diagnosis conditions under the risk adjustment model. These compliance efforts include the internal contract level audits described in more detail below.

CMS is continuing to perform audits of various companies' selected Medicare Advantage contracts related to this risk adjustment diagnosis data. We refer to these audits as Risk-Adjustment Data Validation Audits, or RADV audits. RADV audits review medical records in an attempt to validate provider medical record documentation and coding practices which influence the calculation of premium payments to Medicare Advantage plans.

In 2012, CMS released a Notice of Final Payment Error Calculation Methodology for Part C Medicare Advantage Risk Adjustment Data Validation (RADV) Contract-Level Audits. The payment error calculation methodology provides that, in calculating the economic impact of audit results for a Medicare Advantage contract, if any, the results of the audit sample will be extrapolated to the entire Medicare Advantage contract based upon a comparison to benchmark audit data in the government fee-for-service program. This comparison to the government program benchmark audit is necessary to determine the economic impact, if any, of audit results because the government program data set, including any attendant errors that are present in that data set, provides the basis for Medicare Advantage plans' risk adjustment to payment rates. CMS already makes other adjustments to payment rates based on a comparison of coding pattern differences between Medicare Advantage plans and the government fee-for-service program data (such as for frequency of coding for certain diagnoses in Medicare Advantage plan data versus the government program data set).

The final methodology, including the first application of extrapolated audit results to determine audit settlements, is expected to be applied to the current round of RADV contract level audits being conducted on 2011 premium payments. Selected Medicare Advantage contracts will be notified of an audit at some point after the close of the final reconciliation for the payment year being audited. The final reconciliation occurs in August of the calendar year following the payment year. On November 5, 2013, we were notified that certain of our Medicare Advantage contracts have been selected for audit for contract year 2011.

Estimated audit settlements are recorded as a reduction of premiums revenue in our consolidated statements of income, based upon available information. We perform internal contract level audits based on the RADV audit methodology prescribed by CMS. Included in these internal contract level audits is an audit of our Private Fee-For-Service business which we used to represent a proxy of the benchmark audit data in the government fee-for-service program which has not yet been released. We based our accrual of estimated audit settlements for contract years 2011 (the first year that application of extrapolated audit results is applicable) through 2014 on the results of these internal contract level audits and update our estimates as each audit is completed. Estimates derived from these results were not material to our results of operations, financial position, or cash flows. However, as indicated, we are awaiting additional guidance from CMS regarding the benchmark audit data in the government fee-for-service program. Accordingly, we cannot determine whether such RADV audits will have a material adverse effect on our results of operations, financial position, or cash flows.

In addition, CMS' recent comments in formalized guidance regarding overpayments to Medicare Advantage plans appear to be inconsistent with the Agency's prior RADV audit guidance. These statements, contained in the preamble to CMS' final rule release regarding Medicare Advantage and Part D prescription drug benefit program regulations for Contract Year 2015, appear to equate each Medicare Advantage risk adjustment data error with an overpayment without reconciliation to the principles underlying the FFS Adjuster referenced above. We will continue to work with CMS to ensure that Medicare Advantage plans are paid accurately and that payment model principles are in accordance with the requirements of the Social Security Act, which if not implemented correctly could have a material adverse effect on our results of operations, financial position, or cash flows.

At June 30, 2014, our military services business, which accounted for approximately 1% of our total premiums and services revenue for the six months ended June 30, 2014, primarily consisted of the TRICARE South Region contract. The current 5-year South Region contract, which expires March 31, 2017, is subject to annual renewals on April 1 of each year during its term at the government's option. On March 14, 2014, the Defense Health Agency, or DHA, exercised its option to extend the TRICARE South Region contract through March 31, 2015.

Table of Contents**Humana Inc.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****Unaudited**

The loss of any of the contracts above or significant changes in these programs as a result of legislative or regulatory action, including reductions in premium payments to us, regulatory restrictions on profitability, including by comparison of our Medicare Advantage profitability to our non-Medicare Advantage business profitability and a requirement that they remain within certain ranges of each other, or increases in member benefits without corresponding increases in premium payments to us, may have a material adverse effect on our results of operations, financial position, and cash flows.

Our state-based Medicaid business accounted for approximately 2% of our total premiums and services revenue for the six months ended June 30, 2014. In addition to our state-based Medicaid contracts in Florida and Kentucky, we have contracts in Illinois and Virginia for stand-alone dual eligible demonstration programs serving individuals dually eligible for both the federal Medicare program and the applicable state-based Medicaid program. We began serving members in Illinois in the first quarter of 2014 and in Virginia in the second quarter of 2014. In addition, we began serving members in Long-Term Care Support Services (LTSS) regions in Florida at various effective dates ranging from the second half of 2013 through the first quarter of 2014.

On June 26, 2013, the Puerto Rico Health Insurance Administration notified us of its election not to renew our three-year Medicaid contracts for the East, Southeast, and Southwest regions which ended June 30, 2013. Contractual transition provisions required the continuation of insurance coverage for beneficiaries through September 30, 2013 and also required an additional period of time thereafter to process residual claims.

Legal Proceedings and Certain Regulatory Matters***Florida Matters***

On December 16, 2010, an individual filed a qui tam suit captioned *United States of America ex rel. Marc Osheroff v. Humana et al.* in the Southern District of Florida, against us, several of our health plan subsidiaries, and certain other companies that operate medical centers in Miami-Dade County, Florida. After the U.S. government declined to intervene, the Court ordered the complaint unsealed, and the individual plaintiff amended his complaint and served the Company on December 8, 2011. The amended complaint alleges certain civil violations by our CAC Medical Centers in Florida, including offering various amenities such as transportation and meals, to Medicare and dual eligible individuals in our community center settings. The amended complaint also alleges civil violations by our Medicare Advantage health plans in Florida, arising from the alleged activities of our CAC Medical Centers and the codefendants in the complaint. The amended complaint seeks damages and penalties on behalf of the United States under the Anti-Inducement and Anti-Kickback Statutes and the False Claims Act. On September 28, 2012, the Court dismissed, with prejudice, all causes of action that were asserted in the suit. On November 19, 2013, the individual plaintiff appealed the dismissal of the complaint, and we are awaiting the decision of the Court on the appeal.

On January 6, 2012, the Civil Division of the United States Attorney's Office for the Southern District of Florida advised us that it is seeking documents and information from us and several of our affiliates relating to several matters including the coding of medical claims by one or more South Florida medical providers, and loans to physician

practices. On May 1, 2014, the U.S. government filed a Notice of Non-Intervention in connection with a civil qui tam suit related to one of these matters captioned *United States of America ex rel. Olivia Graves v. Plaza Medical Centers, et al.*, and the Court ordered the complaint unsealed. In the ordinary course, the individual plaintiff may amend the complaint and serve the Company to continue to prosecute the action on her own against us. We continue to cooperate with and respond to information requests from the U.S. Attorney's office. These matters could result in additional qui tam litigation.

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Unaudited

Other Lawsuits and Regulatory Matters

Our current and past business practices are subject to review or other investigations by various state insurance and health care regulatory authorities and other state and federal regulatory authorities. These authorities regularly scrutinize the business practices of health insurance and benefits companies. These reviews focus on numerous facets of our business, including claims payment practices, provider contracting, risk adjustment, competitive practices, commission payments, privacy issues, utilization management practices, pharmacy benefits, access to care, and sales practices, among others. Some of these reviews have historically resulted in fines imposed on us and some have required changes to some of our practices. We continue to be subject to these reviews, which could result in additional fines or other sanctions being imposed on us or additional changes in some of our practices.

We also are involved in various other lawsuits that arise, for the most part, in the ordinary course of our business operations, certain of which may be styled as class-action lawsuits. Among other matters, this litigation may include employment matters, claims of medical malpractice, bad faith, nonacceptance or termination of providers, anticompetitive practices, improper rate setting, provider contract rate disputes, failure to disclose network discounts and various other provider arrangements, general contractual matters, intellectual property matters, and challenges to subrogation practices. For example, a number of hospitals and other providers have asserted that, under their network provider contracts, we are not entitled to reduce Medicare Advantage payments to these providers in connection with changes in Medicare payment systems and in accordance with the Balanced Budget and Emergency Deficit Control Act of 1985, as amended (commonly referred to as sequestration). Those challenges have led and could lead to arbitration demands or other litigation. Also, under state guaranty assessment laws, we may be assessed (up to prescribed limits) for certain obligations to the policyholders and claimants of insolvent insurance companies that write the same line or lines of business as we do.

As a government contractor, we may also be subject to qui tam litigation brought by individuals who seek to sue on behalf of the government, alleging that the government contractor submitted false claims to the government including, among other allegations, those resulting from coding and review practices under the Medicare risk adjustment model. Qui tam litigation is filed under seal to allow the government an opportunity to investigate and to decide if it wishes to intervene and assume control of the litigation. If the government does not intervene, the lawsuit is unsealed, and the individual may continue to prosecute the action on his or her own, on behalf of the government. We also are subject to other allegations of non-performance of contractual obligations to providers, members, and others, including failure to properly pay claims, improper policy terminations, challenges to our implementation of the Medicare Part D prescription drug program and other litigation.

A limited number of the claims asserted against us are subject to insurance coverage. Personal injury claims, claims for extracontractual damages, care delivery malpractice, and claims arising from medical benefit denials are covered by insurance from our wholly owned captive insurance subsidiary and excess carriers, except to the extent that claimants seek punitive damages, which may not be covered by insurance in certain states in which insurance coverage for punitive damages is not permitted. In addition, insurance coverage for all or certain forms of liability has become increasingly costly and may become unavailable or prohibitively expensive in the future.

We record accruals for the contingencies discussed above to the extent that we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. No estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made at this time regarding the matters specifically described above because of the inherently unpredictable nature of legal proceedings, which also may be exacerbated by various factors, including: (i) the damages sought in the proceedings are unsubstantiated or indeterminate; (ii) discovery is not complete; (iii) the proceeding is in its early stages; (iv) the matters present legal uncertainties; (v) there are significant facts in dispute; (vi) there are a large number of parties (including where it is uncertain how liability, if any, will be shared among multiple defendants); or (vii) there is a wide range of potential outcomes.

The outcome of any current or future litigation or governmental or internal investigations, including the matters described above, cannot be accurately predicted, nor can we predict any resulting penalties, fines or other sanctions that may be imposed at the discretion of federal or state regulatory authorities. Nevertheless, it is reasonably possible that any such outcome of litigation, penalties, fines or other sanctions could be substantial, and the outcome of these matters may have a material adverse effect on our results of operations, financial position, and cash flows, and may also affect our reputation.

Table of Contents**Humana Inc.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****Unaudited****12. SEGMENT INFORMATION**

We manage our business with three reportable segments: Retail, Employer Group, and Healthcare Services. In addition, the Other Businesses category includes businesses that are not individually reportable because they do not meet the quantitative thresholds required by generally accepted accounting principles. These segments are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers, as described below. These segment groupings are consistent with information used by our Chief Executive Officer to assess performance and allocate resources.

The Retail segment consists of Medicare and commercial fully-insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products, marketed directly to individuals, and includes our contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible, and Long-Term Support Services benefits, collectively our state-based contracts. The Employer Group segment consists of Medicare and commercial fully-insured medical and specialty health insurance benefits, including dental, vision, and voluntary benefit products, as well as administrative services only, or ASO, products and our health and wellness products primarily marketed to employer groups. The Healthcare Services segment includes services offered to our health plan members as well as to third parties including pharmacy, provider services, home based services, integrated behavioral health services and predictive modeling and informatics services. The Other Businesses category consists of our military services, primarily our TRICARE South Region contract, closed-block of long-term care insurance policies, and our Puerto Rico Medicaid contracts under which coverage was terminated effective September 30, 2013.

Our Healthcare Services intersegment revenues primarily relate to managing prescription drug coverage for members of our other segments through Humana Pharmacy Solutions[®], or HPS, and includes the operations of *RightSourceRx*[®], our mail order pharmacy business. These revenues consist of the prescription price (ingredient cost plus dispensing fee), including the portion to be settled with the member (co-share) or with the government (subsidies), plus any associated administrative fees. Services revenues related to the distribution of prescriptions by third party retail pharmacies in our networks are recognized when the claim is processed and product revenues from dispensing prescriptions from our mail order pharmacies are recorded when the prescription or product is shipped. Our pharmacy operations, which are responsible for designing pharmacy benefits, including defining member co-share responsibilities, determining formulary listings, contracting with retail pharmacies, confirming member eligibility, reviewing drug utilization, and processing claims, act as a principal in the arrangement on behalf of members in our other segments. As principal, our Healthcare Services segment reports revenues on a gross basis including co-share amounts from members collected by third party retail pharmacies at the point of service.

In addition, our Healthcare Services intersegment revenues include revenues earned by certain owned providers derived from risk-based managed care agreements with our health plans. Under these agreements, the provider receives a monthly capitated fee that varies depending on the demographics and health status of the member, for each member assigned to these owned providers by our health plans. The owned provider assumes the economic risk of funding the assigned members' healthcare services and related administrative costs. Accordingly, our Healthcare

Services segment reports provider services related revenues on a gross basis. Capitation fee revenue is recognized in the period in which the assigned members are entitled to receive healthcare services.

We present our consolidated results of operations from the perspective of the health plans. As a result, the cost of providing benefits to our members, whether provided via a third party provider or internally through a stand-alone subsidiary, is classified as benefits expense and excludes the portion of the cost for which the health plans do not bear responsibility, including member co-share amounts and government subsidies of \$2.3 billion and \$1.7 billion for the three months ended June 30, 2014 and 2013, respectively. For the six months ended June 30, 2014 and 2013, these amounts were \$4.1 billion and \$3.2 billion respectively. In addition, depreciation and amortization expense associated with certain businesses in our Healthcare Services segment delivering benefits to our members, primarily associated with our provider services and pharmacy operations, are included with benefits expense. The amount of this expense was \$27 million and \$24 million for the three months ended June 30, 2014 and 2013, respectively. For the six months ended June 30, 2014 and 2013, the amount of this expense was \$52 million and \$46 million, respectively.

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Unaudited

Other than those described previously, the accounting policies of each segment are the same and are described in Note 2 to the consolidated financial statements included in our 2013 Form 10-K. Transactions between reportable segments primarily consist of sales of services rendered by our Healthcare Services segment, primarily pharmacy, provider, and behavioral health services, to our Retail and Employer Group customers. Intersegment sales and expenses are recorded at fair value and eliminated in consolidation. Members served by our segments often use the same provider networks, enabling us in some instances to obtain more favorable contract terms with providers. Our segments also share indirect costs and assets. As a result, the profitability of each segment is interdependent. We allocate most operating expenses to our segments. Assets and certain corporate income and expenses are not allocated to the segments, including the portion of investment income not supporting segment operations, interest expense on corporate debt, and certain other corporate expenses. These items are managed at a corporate level. These corporate amounts are reported separately from our reportable segments and included with intersegment eliminations in the tables presenting segment results below.

Table of Contents**Humana Inc.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****Unaudited**

Our segment results were as follows for the three and six months ended June 30, 2014 and 2013, respectively:

	Retail	Employer Group	Healthcare Services	Other Businesses	Eliminations/ Corporate	Consolidated
	(in millions)					
Three months ended June 30, 2014						
Revenues external customers						
Premiums:						
Medicare Advantage	\$ 6,475	\$ 1,366	\$	\$	\$	\$ 7,841
Medicare stand-alone PDP	939	2				941
Total Medicare	7,414	1,368				8,782
Fully-insured	912	1,321				2,233
Specialty	66	275				341
Military services				4		4
Medicaid and other	206			18		224
Total premiums	8,598	2,964		22		11,584
Services revenue:						
Provider		6	307			313
ASO and other	13	81		114		208
Pharmacy			25			25
Total services revenue	13	87	332	114		546
Total revenues external customers	8,611	3,051	332	136		12,130
Intersegment revenues						
Services		16	3,697		(3,713)	
Products			938		(938)	
Total intersegment revenues		16	4,635		(4,651)	
Investment income	18	11		15	48	92
Total revenues	8,629	3,078	4,967	151	(4,603)	12,222

Edgar Filing: HUMANA INC - Form 10-Q

Operating expenses:

Benefits	7,283	2,472	27	(155)	9,627
Operating costs	982	492	4,726	103	1,835
Depreciation and amortization	35	25	35	4	79
Total operating expenses	8,300	2,989	4,761	134	11,541
Income from operations	329	89	206	17	681
Interest expense				35	35
Income before income taxes	\$ 329	\$ 89	\$ 206	\$ 17	\$ 646

Table of Contents**Humana Inc.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****Unaudited**

	Retail	Employer Group	Healthcare Services	Other Businesses	Eliminations/ Corporate	Consolidated
	(in millions)					
Three months ended June 30, 2013						
Revenues external customers						
Premiums:						
Medicare Advantage	\$ 5,572	\$ 1,160	\$	\$	\$	\$ 6,732
Medicare stand-alone PDP	785	2				787
Total Medicare	6,357	1,162				7,519
Fully-insured	285	1,273				1,558
Specialty	52	275				327
Military services				5		5
Medicaid and other	72			220		292
Total premiums	6,766	2,710		225		9,701
Services revenue:						
Provider		5	312			317
ASO and other	2	82		114		198
Pharmacy			13			13
Total services revenue	2	87	325	114		528
Total revenues external customers	6,768	2,797	325	339		10,229
Intersegment revenues						
Services		12	2,906		(2,918)	
Products			680		(680)	
Total intersegment revenues		12	3,586		(3,598)	
Investment income	18	10		15	49	92
Total revenues	6,786	2,819	3,911	354	(3,549)	10,321
Operating expenses:						
Benefits	5,696	2,235		251	(91)	8,091
Operating costs	640	423	3,751	129	(3,482)	1,461

Edgar Filing: HUMANA INC - Form 10-Q

Depreciation and amortization	32	27	36	4	(19)	80
Total operating expenses	6,368	2,685	3,787	384	(3,592)	9,632
Income (loss) from operations	418	134	124	(30)	43	689
Interest expense					35	35
Income (loss) before income taxes	\$ 418	\$ 134	\$ 124	\$ (30)	\$ 8	\$ 654

Table of Contents**Humana Inc.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****Unaudited**

	Retail	Employer Group	Healthcare Services	Other Businesses	Eliminations/ Corporate	Consolidated
	(in millions)					
Six months ended June 30, 2014						
Revenues external customers						
Premiums:						
Medicare Advantage	\$ 12,935	\$ 2,750	\$	\$	\$	\$ 15,685
Medicare stand-alone PDP	1,802	4				1,806
Total Medicare	14,737	2,754				17,491
Fully-insured	1,437	2,650				4,087
Specialty	125	550				675
Military services				10		10
Medicaid and other	375			29		404
Total premiums	16,674	5,954		39		22,667
Services revenue:						
Provider		11	597			608
ASO and other	27	162		241		430
Pharmacy			46			46
Total services revenue	27	173	643	241		1,084
Total revenues external customers	16,701	6,127	643	280		23,751
Intersegment revenues						
Services		35	7,151		(7,186)	
Products			1,784		(1,784)	
Total intersegment revenues		35	8,935		(8,970)	
Investment income	37	21		30	95	183
Total revenues	16,738	6,183	9,578	310	(8,875)	23,934
Operating expenses:						
Benefits	14,170	4,828		55	(302)	18,751
Operating costs	1,905	991	9,116	205	(8,597)	3,620

Edgar Filing: HUMANA INC - Form 10-Q

Depreciation and amortization	72	49	71	8	(39)	161
Total operating expenses	16,147	5,868	9,187	268	(8,938)	22,532
Income from operations	591	315	391	42	63	1,402
Interest expense					70	70
Income (loss) before income taxes	\$ 591	\$ 315	\$ 391	\$ 42	\$ (7)	\$ 1,332

Table of Contents**Humana Inc.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****Unaudited**

	Retail	Employer Group	Healthcare Services	Other Businesses	Eliminations/ Corporate	Consolidated
	(in millions)					
Six months ended June 30, 2013						
Revenues external customers						
Premiums:						
Medicare Advantage	\$ 11,308	\$ 2,350	\$	\$	\$	\$ 13,658
Medicare stand-alone PDP	1,546	4				1,550
Total Medicare	12,854	2,354				15,208
Fully-insured	564	2,541				3,105
Specialty	101	550				651
Military services				16		16
Medicaid and other	151			438		589
Total premiums	13,670	5,445		454		19,569
Services revenue:						
Provider		9	618			627
ASO and other	4	166		234		404
Pharmacy			22			22
Total services revenue	4	175	640	234		1,053
Total revenues external customers	13,674	5,620	640	688		20,622
Intersegment revenues						
Services		23	5,707		(5,730)	
Products			1,334		(1,334)	
Total intersegment revenues		23	7,041		(7,064)	
Investment income	36	21		30	98	185
Total revenues	13,710	5,664	7,681	718	(6,966)	20,807
Operating expenses:						
Benefits	11,625	4,412		438	(189)	16,286
Operating costs	1,253	856	7,367	244	(6,813)	2,907

Edgar Filing: HUMANA INC - Form 10-Q

Depreciation and amortization	64	50	72	8	(34)	160
Total operating expenses	12,942	5,318	7,439	690	(7,036)	19,353
Income from operations	768	346	242	28	70	1,454
Interest expense					70	70
Income before income taxes	\$ 768	\$ 346	\$ 242	\$ 28	\$	\$ 1,384

Table of Contents**Humana Inc.****ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

The condensed consolidated financial statements of Humana Inc. in this document present the Company's financial position, results of operations and cash flows, and should be read in conjunction with the following discussion and analysis. References to we, us, our, Company, and Humana mean Humana Inc. and its subsidiaries. This discussion includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in filings with the SEC, in our press releases, investor presentations, and in oral statements made by or with the approval of one of our executive officers, the words or phrases like believes, expects, anticipates, intends, likely will result, estimates, projects or variations of such words and similar expressions are intended to identify such forward looking statements. These forward looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions, including, among other things, information set forth in Item 1A. Risk Factors in our 2013 Form 10-K, as modified by any changes to those risk factors included in this document and in other reports we filed subsequent to February 19, 2014, in each case incorporated by reference herein. In making these statements, we are not undertaking to address or update such forward-looking statements in future filings or communications regarding our business or results. In light of these risks, uncertainties and assumptions, the forward looking events discussed in this document might not occur. There may also be other risks that we are unable to predict at this time. Any of these risks and uncertainties may cause actual results to differ materially from the results discussed in the forward looking statements.

Executive Overview***General***

Humana Inc., headquartered in Louisville, Ky., is a leading health and well-being company focused on making it easy for people to achieve their best health with clinical excellence through coordinated care. The company's strategy integrates care delivery, the member experience, and clinical and consumer insights to encourage engagement, behavior change, proactive clinical outreach and wellness for the millions of people we serve across the country.

Our industry relies on two key statistics to measure performance. The benefit ratio, which is computed by taking total benefits expense as a percentage of premiums revenue, represents a statistic used to measure underwriting profitability. The operating cost ratio, which is computed by taking total operating costs as a percentage of total revenue less investment income, represents a statistic used to measure administrative spending efficiency.

Business Segments

On January 1, 2014, we reclassified certain of our businesses from our Healthcare Services segment to our Employer Group segment to correspond with internal management reporting changes. Our reportable segments remain the same and prior period segment financial information has been recast to conform to the 2014 presentation.

We manage our business with three reportable segments: Retail, Employer Group, and Healthcare Services. In addition, the Other Businesses category includes businesses that are not individually reportable because they do not meet the quantitative thresholds required by generally accepted accounting principles. These segments are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers, as described below. These segment groupings are consistent with information used

by our Chief Executive Officer to assess performance and allocate resources.

The Retail segment consists of Medicare and commercial fully-insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products, marketed directly to individuals, and includes our contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible, and Long-Term Support Services benefits, collectively our state-based contracts. The Employer Group segment consists of Medicare and commercial fully-insured medical and specialty health insurance benefits, including dental, vision, and voluntary benefit products, as well as administrative services only, or ASO, products and our health and wellness products primarily marketed to employer groups. The Healthcare Services segment includes services offered to our health plan members as well as to third parties including pharmacy, provider services, home based services, integrated behavioral health services and predictive modeling and informatics services. The Other Businesses category consists of our military services, primarily our TRICARE South Region contract, closed-block of long-term care insurance policies, and our Puerto Rico Medicaid contracts under which coverage was terminated effective September 30, 2013.

Table of Contents

The results of each segment are measured by income before income taxes. Transactions between reportable segments primarily consist of sales of services rendered by our Healthcare Services segment, primarily pharmacy, provider, and behavioral health services, to our Retail and Employer Group customers. Intersegment sales and expenses are recorded at fair value and eliminated in consolidation. Members served by our segments often use the same provider networks, enabling us in some instances to obtain more favorable contract terms with providers. Our segments also share indirect costs and assets. As a result, the profitability of each segment is interdependent. We allocate most operating expenses to our segments. Assets and certain corporate income and expenses are not allocated to the segments, including the portion of investment income not supporting segment operations, interest expense on corporate debt, and certain other corporate expenses. These items are managed at a corporate level. These corporate amounts are reported separately from our reportable segments and included with intersegment eliminations.

Seasonality

One of the product offerings of our Retail segment is Medicare stand-alone prescription drug plans, or PDPs, under the Medicare Part D program. These plans provide varying degrees of coverage. Our quarterly Retail segment earnings and operating cash flows are impacted by the Medicare Part D benefit design and changes in the composition of our membership. The Medicare Part D benefit design results in coverage that varies as a member's cumulative out-of-pocket costs pass through successive stages of a member's plan period, which begins annually on January 1 for renewals. These plan designs generally result in us sharing a greater portion of the responsibility for total prescription drug costs in the early stages and less in the latter stages. As a result, the PDP benefit ratio generally decreases as the year progresses. In addition, the number of low-income senior members as well as year-over-year changes in the mix of membership in our stand-alone PDP products affects the quarterly benefit ratio pattern.

Our Employer Group segment also experiences seasonality in the benefit ratio pattern. However, the effect is opposite of Medicare stand-alone PDP in the Retail segment, with the Employer Group's benefit ratio increasing as fully-insured members progress through their annual deductible and maximum out-of-pocket expenses. Similarly, certain of our fully-insured individual commercial medical products in our Retail segment experience seasonality in the benefit ratio akin to the Employer Group segment; however, we expect our new plans compliant with the Health Care Reform Law to experience less seasonality than our historical individual commercial medical products.

In addition, the Retail segment also experiences seasonality in the operating cost ratio as a result of costs incurred in the second half of the year associated with the Medicare and individual health care exchange marketing seasons.

2014 Highlights***Consolidated***

Our 2014 results reflect the continued implementation of our strategy to offer our members affordable health care combined with a positive consumer experience in growing markets. At the core of this strategy is our integrated care delivery model, which unites quality care, high member engagement, and sophisticated data analytics. Our approach to primary, physician-directed care for our members aims to provide quality care that is consistent, integrated, cost-effective, and member-focused, provided by both employed physicians and physicians with network contract arrangements. The model is designed to improve health outcomes and affordability for individuals and for the health system as a whole, while offering our members a simple, seamless healthcare experience. We believe this strategy is positioning us for long-term growth in both membership and earnings. At June 30, 2014, approximately 659,200 members, or 27.9%, of our individual

Medicare Advantage membership were in risk arrangements under our integrated care delivery model, as compared to 561,500 members, or 27.1%, at December 31, 2013 and 541,400 members, or 26.7%, at June 30, 2013.

Table of Contents

Our results for the three and six months ended June 30, 2014 as compared to the three and six months ended June 30, 2013, were impacted by investments in health care exchanges and new state-based contracts and higher specialty prescription drug costs associated with a new treatment for Hepatitis C, partially offset by membership growth in our Medicare Advantage, Medicare stand-alone PDP, and individual commercial medical offerings. In addition, year-over-year comparisons were also negatively impacted by sequestration which became effective April 1, 2013.

Year-over-year comparisons of the operating cost ratio are impacted by fees mandated by the Health Care Reform Law beginning in 2014, including the non-deductible health insurance industry fee. Likewise, year-over-year comparisons of the benefit ratio reflect the inclusion of these mandated fees in the pricing of our products for 2014.

Year-over-year comparisons of diluted earnings per common share are favorably impacted by a lower number of shares used to compute diluted earnings per common share reflecting the impact of share repurchases.

Our operating cash flow of \$471 million for the six months ended June 30, 2014 compared to operating cash flow of \$585 million for the six months ended June 30, 2013. Our operating cash flows for 2014 reflect earnings and enrollment activity and the timing of working capital items including the timing of receipts and payments under certain provisions of the Health Care Reform Law that became effective in 2014. For 2014, the effect of the commercial risk adjustment, risk corridor, and reinsurance provisions of the Health Care Reform Law are impacting the timing of our operating cash flows, as we expect to build a receivable in 2014 that will be collected in 2015. It is reasonably possible that the receivable could be material to our operating cash flow in 2014. In 2014, we expect our operating cash flows to decline from 2013.

We expect our 2014 financing cash flows to be negatively impacted by the timing of payments to and receipts from CMS associated with Medicare Part D reinsurance subsidies for which we do not assume risk. We are experiencing higher specialty prescription drug costs associated with a new treatment for Hepatitis C than were contemplated in our bids which is resulting in higher reinsurance subsidy receivable balances in 2014 that will be settled in 2015 under the terms of our contracts with CMS.

In September 2014, we expect to pay the federal government approximately \$560 million for the annual health insurance industry fee. This fee is not deductible for tax purposes, which has significantly increased our effective income tax rate in 2014. The health insurance industry fee is further described below under the section titled Health Care Reform.

During the six months ended June 30, 2014, we repurchased 0.91 million shares in open market transactions for \$112 million and paid dividends to stockholders of \$86 million.

Retail

On April 7, 2014, CMS announced final 2015 Medicare benchmark payment rates and related technical factors impacting the bid benchmark premiums, which we refer to as the Final Rate Notice. We believe the Final Rate Notice together with the impact of payment cuts associated with the Health Care Reform Law, quality bonuses, sunset of the Star quality CMS demonstration in 2015, risk coding modifications, the impact of the health insurance industry fee, and other funding formula changes, indicate 2015 Medicare Advantage funding cuts of approximately 2%. While we believe our senior members' benefits may be adversely impacted, we believe we can effectively design Medicare Advantage products based upon these levels of rate reduction while continuing to remain competitive compared to both the combination of original Medicare with a supplement policy as well as Medicare Advantage products offered by our competitors. Failure to execute these strategies may result in a material adverse effect on our results of operations, financial position, and cash flows.

Automatic across-the-board budget cuts under the Budget Control Act of 2011 and the American Taxpayer Relief Act of 2012, known as sequestration, commenced in March 2013, including a 2% reduction in Medicare Advantage and Medicare Part D payments beginning April 1, 2013. While we believe we can reduce Medicare Advantage payments to providers under our network provider contracts in connection with sequestration, a number of hospitals and other providers have asserted that we are not entitled to do so, which have led and may lead to arbitration demands or other litigation regarding these matters.

Table of Contents

For the six months ended June 30, 2014, our Retail segment pretax income declined by \$177 million, or 23.0%, primarily driven by the same factors impacting our consolidated results as described above.

Individual Medicare Advantage membership of 2,363,000 at June 30, 2014 increased 294,300, or 14.2%, from 2,068,700 at December 31, 2013 and increased 333,300 members, or 16.4%, from 2,029,700 at June 30, 2013 reflecting net membership additions, particularly for our Health Maintenance Organization, or HMO, offerings, for the 2014 plan year.

Medicare stand-alone PDP membership of 3,881,100 at June 30, 2014 increased 609,400 members, or 18.6%, from 3,271,700 at December 31, 2013 and increased 660,500 members, or 20.5%, from 3,220,600 at June 30, 2013 reflecting net membership additions, primarily for our Humana-Walmart plan offering for the 2014 plan year.

The addition of our Florida Long-Term Support Services contracts added 17,900 members to our state-based Medicaid membership as of June 30, 2014 compared to June 30, 2013.

Individual commercial medical membership of 1,244,300 at June 30, 2014 increased 644,200 members, or 107.3%, from 600,100 at December 31, 2013 and increased 676,000 members, or 119.0%, from 568,300 at June 30, 2013 primarily reflecting new sales, both on-exchange and off-exchange, of plans compliant with the Health Care Reform Law. In addition, federal and state regulatory changes in December 2013 allowed certain individuals to remain in their existing underwritten health plans that are not compliant with the Health Care Reform Law, which has led to much higher than previously expected retention of our existing underwritten health plans. We believe that this is occurring at other health insurance issuers as well and will result in an overall deterioration of the risk pool in plans compliant with the Health Care Reform Law, as more previously underwritten members remain with their current health plans rather than enter the exchanges. However, we expect that the commercial risk adjustment, risk corridor, and reinsurance provisions of the Health Care Reform Law will mitigate this deterioration to some extent.

Employer Group Segment

As discussed in the detailed Employer Group segment results of operations discussion that follows, the Employer Group segment benefit ratio increased 90 basis points to 83.4% for the three months ended June 30, 2014 and increased 10 basis points to 81.1% for the six months ended June 30, 2014.

Fully-insured group Medicare Advantage membership of 479,700 at June 30, 2014 increased 50,600 members, or 11.8%, from 429,100 at December 31, 2013 and increased 63,100 members, or 15.1%, from 416,600 at June 30, 2013 primarily due to the January 2014 addition of a new large group account.

Membership in HumanaVitality®, our wellness and loyalty rewards program, rose 33.2% to 3,772,000 at June 30, 2014 from 2,831,000 at December 31, 2013 and rose 38.8% from 2,717,800 at June 30, 2013 primarily due to the addition of group Medicare members as well as individual Medicare Advantage and

fully-insured individual commercial medical membership growth.

Healthcare Services Segment

As discussed in the detailed Healthcare Services segment results of operations discussion that follows, our Healthcare Services segment pretax income improved 66.1% for the 2014 quarter as compared to the 2013 quarter and 61.6% for the 2014 period as compared to the 2013 period primarily due to revenue growth and pretax income contribution from our pharmacy solutions and home based services businesses as they serve our growing medical membership.

Programs to enhance the quality of care for members are key elements of our integrated care delivery model. We have accelerated our process for identifying and reaching out to members in need of clinical intervention. At June 30, 2014, we had approximately 344,500 members with complex chronic conditions in the Humana Chronic Care Program, a 22.9% increase compared with approximately 280,200 members at December 31, 2013, and an increase of 62.5% compared with approximately 212,000 members at June 30, 2013. These increases reflect enhanced predictive modeling capabilities and focus on proactive clinical outreach and member engagement, particularly for our Medicare Advantage membership. We believe these initiatives lead to better health outcomes for our members and lower health care costs.

Table of Contents*Other Businesses*

Year-over-year comparisons within Other Businesses are impacted by the loss of our Medicaid contracts in Puerto Rico effective September 30, 2013 and a reduction in benefits expense for the six months ended June 30, 2013 related to a favorable settlement of contract claims with the United States Department of Defense, or DoD, associated with previously disclosed litigation.

Health Care Reform

The Health Care Reform Law enacted significant reforms to various aspects of the U.S. health insurance industry. While regulations and interpretive guidance on many provisions of the Health Care Reform Law have been issued to date by the Department of Health and Human Services, or HHS, the Department of Labor, the Treasury Department, and the National Association of Insurance Commissioners, or NAIC, there are certain provisions of the law that will require additional guidance and clarification in the form of regulations and interpretations in order to fully understand the impact of the law on our overall business.

Implementation dates of the Health Care Reform Law began in September 2010 and will continue through 2018, and many aspects of the Health Care Reform Law are already effective and have been implemented by us. Certain significant provisions of the Health Care Reform Law include, among others, mandated coverage requirements, mandated benefits and guarantee issuance associated with commercial medical insurance, rebates to policyholders based on minimum benefit ratios, adjustments to Medicare Advantage premiums, the establishment of federally-facilitated or state-based exchanges coupled with programs designed to spread risk among insurers, an annual insurance industry premium-based assessment, and a three-year commercial reinsurance fee. The following outlines certain provisions of the Health Care Reform Law:

Currently Effective with Phased-In Implementation: In 2012, additional cuts to Medicare Advantage plan payment benchmarks began to take effect (with plan payment benchmarks ultimately ranging from 95% in high-cost areas to 115% in low-cost areas of Medicare fee-for-service rates), with changes being phased-in over two to six years, depending on the level of payment reduction in a county. In addition, since 2011 the gap in coverage for Medicare Part D prescription drug coverage has been incrementally closing.

Certain provisions in the Health Care Reform Law tie Medicare Advantage premiums to the achievement of certain quality performance measures (Star Ratings). Beginning in 2012, Medicare Advantage plans with an overall Star Rating of three or more stars (out of five) were eligible for a quality bonus in their basic premium rates. By law, quality bonuses were limited to the few plans that achieved four or more stars as an overall rating, but CMS, through its demonstration authority, expanded the quality bonus to three Star plans for a three-year period through 2014. Beginning in 2015, quality bonus amounts will be determined by the provisions in the Health Care Reform Law. In part, this means that plans must have a Star Rating of four or higher to qualify for bonus money. Star Ratings issued by CMS in October 2013 indicated that 55% to 60% of our Medicare Advantage members are now in plans that will qualify for quality bonus payments in 2015, down from 99% in 2014, primarily due to an increase in the required minimum overall Star program rating from three stars in 2014 to four stars in 2015. Beginning in 2015, plans must have a Star Rating of four or higher to qualify for quality bonuses in the basic premium rates. We have 18 Medicare Advantage plans that achieved a rating of four or more stars, an increase of 50% from the previous year. We are offering nine Medicare Advantage plans that achieved a 4.5 Star Rating. Plans that earn an overall Star Rating of five continue to be eligible to enroll members year round. Notwithstanding successful historical efforts to improve our Star Ratings and other quality measures, there can be no assurances that we will be successful in maintaining or improving

our Star Ratings in future years. Additionally, as a result of the expiration of a CMS quality bonus demonstration, for plans that maintain a four Star or higher rating in 2015, other provisions of the Health Care Reform Law may, in certain areas of the country, reduce the amount of the quality bonus that is added to the basic premium rate. Accordingly, our plans may not be eligible for full level quality bonuses, which, in isolation, could adversely affect the benefits such plans can offer, reduce membership, and/or reduce profit margins.

Table of Contents

In addition, on March 31, 2014, with certain exceptions, we completed the initial open enrollment period for plans offered through federally-facilitated, federal-state partnerships or state-based exchanges for individuals in certain metropolitan areas in the 14 states where we have public exchange offerings.

Newly Effective in 2014: Beginning in 2014, the Health Care Reform Law requires: all individual and group health plans to guarantee issuance and renew coverage without pre-existing condition exclusions or health-status rating adjustments; the elimination of annual limits on coverage on certain benefits; the establishment of federally-facilitated, federal-state partnerships or state-based exchanges for individuals and small employers (with up to 100 employees) coupled with programs designed to spread risk among insurers; the introduction of plan designs based on set actuarial values; the establishment of a minimum benefit ratio of 85% for Medicare Advantage plans; and insurance industry assessments, including an annual health insurance industry fee and a three-year \$25 billion industry wide commercial reinsurance fee. The annual health insurance industry fee levied on the insurance industry is \$8 billion in 2014 with increasing annual amounts thereafter, growing to \$14 billion by 2017, and is not deductible for income tax purposes, which will significantly increase our effective income tax rate in 2014 to approximately 46% to 47%. In addition, statutory accounting for the health insurance industry fee requires us to restrict surplus in the year preceding payment of the health insurance industry fee beginning in 2014. Accordingly, in addition to recording the full-year 2014 assessment in the first quarter of 2014, we are required to restrict surplus for the 2015 assessment ratably in 2014. In 2014, we expect to pay the federal government approximately \$560 million for the annual health insurance industry fee. In 2015, the health insurance industry fee increases by 41% for the industry taken as a whole. Accordingly, absent changes in market share, we would expect a similar increase in our fee in 2015.

The Health Care Reform Law also specifies benefit design guidelines, limits rating and pricing practices, encourages additional competition from the establishment of two multi-state plans (one not-for-profit; one for-profit) administered through the Office of Personnel Management, and expands eligibility for Medicaid programs. In addition, the Health Care Reform Law has increased and will continue to increase federal oversight of health plan premium rates and could adversely affect our ability to appropriately adjust health plan premiums on a timely basis. Financing for these reforms comes, in part, from material additional fees and taxes on us (as discussed above) and other health plans and individuals beginning in 2014, as well as reductions in certain levels of payments to us and other health plans under Medicare as described in this report.

As discussed above, implementing regulations and related interpretive guidance continue to be issued on certain provisions of the Health Care Reform Law. Given the breadth of possible changes and the uncertainties of interpretation, implementation, and timing of these changes, the Health Care Reform Law has and will change the way we do business, impacting our pricing, benefit design, product mix, geographic mix, and distribution channels. The response of other companies to the Health Care Reform Law and adjustments to their and our offerings could cause meaningful disruption in local health care markets. It is reasonably possible that the Health Care Reform Law and related regulations, as well as future legislative changes, including legislative restrictions on our ability to manage our provider network or otherwise operate our business, or regulatory restrictions on profitability, including by comparison of our Medicare Advantage profitability to our non-Medicare Advantage business profitability and a requirement that they remain within certain ranges of each other, in the aggregate may have a material adverse effect on our results of operations (including restricting revenue, enrollment and premium growth in certain products and market segments, restricting our ability to expand into new markets, increasing our medical and operating costs, further lowering our Medicare payment rates and increasing our expenses associated with the non-deductible health insurance industry fee and other assessments); our financial position (including our ability to maintain the value of our goodwill); and our cash flows (including the receipt of amounts due under the commercial risk adjustment, risk corridor, and reinsurance provisions of the Health Care Reform Law in 2015 related to claims paid in 2014). If we are

unable to adjust our business model to address the non-deductible health insurance industry fee and other assessments, including the three-year commercial reinsurance fee, such as through the reduction of our operating costs or adjustments to premium pricing or benefit design, there can be no assurance that the non-deductible health insurance industry fee and other assessments would not have a material adverse effect on our results of operations, financial position, and cash flows.

Table of Contents

We intend for the discussion of our financial condition and results of operations that follows to assist in the understanding of our financial statements and related changes in certain key items in those financial statements from year to year, including the primary factors that accounted for those changes. Transactions between reportable segments primarily consist of sales of services rendered by our Healthcare Services segment, primarily pharmacy, provider, and behavioral health services, to our Retail and Employer Group customers and are described in Note 12 to the condensed consolidated financial statements.

Comparison of Results of Operations for 2014 and 2013

The following discussion primarily deals with our results of operations for the three months ended June 30, 2014, or the 2014 quarter, the three months ended June 30, 2013, or the 2013 quarter, the six months ended June 30, 2014, or the 2014 period, and the six months ended June 30, 2013, or the 2013 period.

Consolidated

	For the three months ended June 30,		Change	
	2014	2013	Dollars	Percentage
(dollars in millions, except per common share results)				
Revenues:				
Premiums:				
Retail	\$ 8,598	\$ 6,766	\$ 1,832	27.1%
Employer Group	2,964	2,710	254	9.4%
Other Businesses	22	225	(203)	(90.2)%
Total premiums	11,584	9,701	1,883	19.4%
Services:				
Retail	13	2	11	550%
Employer Group	87	87		%
Healthcare Services	332	325	7	2.2%
Other Businesses	114	114		%
Total services	546	528	18	3.4%
Investment income	92	92		%
Total revenues	12,222	10,321	1,901	18.4%
Operating expenses:				
Benefits	9,627	8,091	1,536	19.0%
Operating costs	1,835	1,461	374	25.6%
Depreciation and amortization	79	80	(1)	(1.3)%
Total operating expenses	11,541	9,632	1,909	19.8%

Edgar Filing: HUMANA INC - Form 10-Q

Income from operations	681	689	(8)	(1.2)%
Interest expense	35	35		%
Income before income taxes	646	654	(8)	(1.2)%
Provision for income taxes	302	234	68	29.1%
Net income	\$ 344	\$ 420	\$ (76)	(18.1)%
Diluted earnings per common share	\$ 2.19	\$ 2.63	\$ (0.44)	(16.7)%
Benefit ratio(a)	83.1%	83.4%		(0.3)%
Operating cost ratio(b)	15.1%	14.3%		0.8%
Effective tax rate	46.7%	35.7%		11.0%

(a) Represents total benefits expense as a percentage of premiums revenue.

(b) Represents total operating costs as a percentage of total revenues less investment income.

Table of Contents

	For the six months ended		Change	
	2014	2013	Dollars	Percentage
(dollars in millions, except per common share results)				
Revenues:				
Premiums:				
Retail	\$ 16,674	\$ 13,670	\$ 3,004	22.0%
Employer Group	5,954	5,445	509	9.3%
Other Businesses	39	454	(415)	(91.4)%
Total premiums	22,667	19,569	3,098	15.8%
Services:				
Retail	27	4	23	575%
Employer Group	173	175	(2)	(1.1)%
Healthcare Services	643	640	3	0.5%
Other Businesses	241	234	7	3.0%
Total services	1,084	1,053	31	2.9%
Investment income	183	185	(2)	(1.1)%
Total revenues	23,934	20,807	3,127	15.0%
Operating expenses:				
Benefits	18,751	16,286	2,465	15.1%
Operating costs	3,620	2,907	713	24.5%
Depreciation and amortization	161	160	1	0.6%
Total operating expenses	22,532	19,353	3,179	16.4%
Income from operations	1,402	1,454	(52)	(3.6)%
Interest expense	70	70		%
Income before income taxes	1,332	1,384	(52)	(3.8)%
Provision for income taxes	620	491	129	26.3%
Net income	\$ 712	\$ 893	\$ (181)	(20.3)%
Diluted earnings per common share	\$ 4.54	\$ 5.58	\$ (1.04)	(18.6)%
Benefit ratio(a)	82.7%	83.2%		(0.5)%
Operating cost ratio(b)	15.2%	14.1%		1.1%
Effective tax rate	46.5%	35.5%		11.0%

(a) Represents total benefits expense as a percentage of premiums revenue.

(b) Represents total operating costs as a percentage of total revenues less investment income.

Table of Contents*Summary*

Net income was \$344 million, or \$2.19 per diluted common share, in the 2014 quarter compared to \$420 million, or \$2.63 per diluted common share, in the 2013 quarter. Net income was \$712 million, or \$4.54 per diluted common share, in the 2014 period compared to \$893 million, or \$5.58 per diluted common share, in the 2013 period. These decreases were primarily due to investments in health care exchanges and new state-based contracts and higher specialty prescription drug costs associated with a new treatment for Hepatitis C. These items were partially offset by membership growth in our Medicare Advantage, Medicare stand-alone PDP, and individual commercial medical offerings. Year-over-year comparisons were also negatively impacted by sequestration which became effective April 1, 2013. In addition, our diluted earnings per common share for the 2013 period included the benefit of a reduction in benefits expense related to a favorable settlement of contract claims with the DoD, partially offset by costs in the 2013 quarter associated with the loss of our Medicaid contracts in Puerto Rico. Year-over-year comparisons of diluted earnings per common share are also favorably impacted by a lower number of shares used to compute diluted earnings per common share in the 2014 quarter and period reflecting the impact of share repurchases.

Premiums

Consolidated premiums increased \$1.9 billion, or 19.4%, from the 2013 quarter to \$11.6 billion for the 2014 quarter and increased \$3.1 billion, or 15.8%, from the 2013 period to \$22.7 billion for the 2014 period. These increases are primarily due to increases in both Retail and Employer Group segment premiums mainly driven by higher average individual and group Medicare Advantage membership as well as higher individual commercial medical membership, partially offset by the impact of sequestration which became effective April 1, 2013. Premiums revenue for our Other Businesses declined primarily due to the loss of our Puerto Rico Medicaid contracts effective September 30, 2013. Average membership is calculated by summing the ending membership for each month in a period and dividing the result by the number of months in a period. Premiums revenue reflects changes in membership and average per member premiums. Items impacting average per member premiums include changes in premium rates as well as changes in the geographic mix of membership, the mix of product offerings, and the mix of benefit plans selected by our membership.

Services revenue

Consolidated services revenue increased \$18 million, or 3.4%, from the 2013 quarter to \$546 million for the 2014 quarter and increased \$31 million, or 2.9%, from the 2013 period to \$1.1 billion for the 2014 period. These increases are primarily due to an increase in services revenue in our Retail segment due to the acquisition of American Eldercare in September 2013.

Investment income

Investment income totaled \$92 million for each of the 2014 quarter and 2013 quarter and was \$183 million for the 2014 period as compared to \$185 million for the 2013 period as higher average invested balances were more than offset by lower interest rates.

Benefits expense

Consolidated benefits expense was \$9.6 billion for the 2014 quarter, an increase of \$1.5 billion, or 19.0%, from the 2013 quarter. For the 2014 period, benefits expense was \$18.8 billion, an increase of \$2.5 billion, or 15.1%, from the 2013 period. These increases are primarily due to increases in both Retail and Employer Group segments mainly driven by higher average individual and group Medicare Advantage membership as well as higher individual

commercial medical membership. We experienced favorable medical claims reserve development related to prior fiscal years of \$49 million in the 2014 quarter as compared to \$100 million in the 2013 quarter, and \$346 million in the 2014 period as compared to \$366 million in the 2013 period. These decreases primarily result from prior year claims reprocessing in the 2014 quarter and period attributable to retroactive adjustments from policy extensions mandated by the Health Care Reform Law, increased severity of 2013 claims for fully insured commercial group business, and, to a lesser extent, improvements in claims processing and front end audits in 2014.

Table of Contents

The consolidated benefit ratio for the 2014 quarter was 83.1%, a 30 basis point decrease from the 2013 quarter. The consolidated benefit ratio for the 2014 period was 82.7%, a 50 basis point decrease from the 2013 period. The decreases in the 2014 quarter and period are primarily due to the loss of our Medicaid contracts in Puerto Rico effective September 30, 2013 which more than offset higher ratios year-over-year in the Retail and Employer Group segments.

Operating costs

Our segments incur both direct and shared indirect operating costs. We allocate the indirect costs shared by the segments primarily as a function of revenues. As a result, the profitability of each segment is interdependent.

Consolidated operating costs increased \$374 million, or 25.6%, during the 2014 quarter compared to the 2013 quarter and increased \$713 million, or 24.5%, during the 2014 period compared to the 2013 period. These increases are primarily due to costs mandated by the Health Care Reform Law, including the non-deductible health insurance industry fee, higher commission expenses for new Medicare Advantage members, and investments in health care exchanges and new state-based contracts.

The consolidated operating cost ratio for the 2014 quarter was 15.1%, increasing 80 basis points from the 2013 quarter. The consolidated operating cost ratio for the 2014 period was 15.2%, increasing 110 basis points from the 2013 period. These increases are primarily due to increases in the operating cost ratios in our Retail and Employer Group segments due to the same factors impacting consolidated operating costs as described above.

Depreciation and amortization

Depreciation and amortization for the 2014 quarter totaled \$79 million, comparable to \$80 million for the 2013 quarter. For the 2014 period, depreciation and amortization of \$161 million compared to \$160 million for the 2013 period.

Interest expense

Interest expense of \$35 million for the 2014 quarter and \$70 million for the 2014 period was comparable to that of the 2013 quarter and 2013 period, respectively.

Income Taxes

Our effective tax rate during the 2014 quarter was 46.7% compared to the effective tax rate of 35.7% in the 2013 quarter. For the 2014 period our effective tax rate was 46.5% compared to the effective tax rate of 35.5% for the 2013 period. The non-deductible nature of the health insurance industry fee levied on the insurance industry beginning in 2014 as mandated by the Health Care Reform Law increased our effective tax rate by approximately 9 percentage points for the 2014 period. In addition, the effective tax for the 2013 quarter and 2013 period includes the beneficial effect of a change in our estimated tax liability associated with limitations on the deductibility of annual compensation in excess of \$500,000 per employee as mandated by the Health Care Reform Law.

Table of Contents**Retail Segment**

	June 30,		Change	
	2014	2013	Members	Percentage
Membership:				
Medical membership:				
Individual Medicare Advantage	2,363,000	2,029,700	333,300	16.4%
Medicare stand-alone PDP	3,881,100	3,220,600	660,500	20.5%
Total Retail Medicare	6,244,100	5,250,300	993,800	18.9%
Individual commercial	1,244,300	568,300	676,000	119.0%
State-based Medicaid	163,000	70,600	92,400	130.9%
Total Retail medical members	7,651,400	5,889,200	1,762,200	29.9%
Individual specialty membership (a)	1,229,500	1,011,700	217,800	21.5%

- (a) Specialty products include dental, vision, and other supplemental health and financial protection products. Members included in these products may not be unique to each product since members have the ability to enroll in multiple products.

	For the three months ended June 30,		Change	
	2014	2013	Dollars	Percentage
	(in millions)			
Premiums and Services Revenue:				
Premiums:				
Individual Medicare Advantage	\$ 6,475	\$ 5,572	\$ 903	16.2%
Medicare stand-alone PDP	939	785	154	19.6%
Total Retail Medicare	7,414	6,357	1,057	16.6%
Individual commercial	912	285	627	220.0%
State-based Medicaid	206	72	134	186.1%
Individual specialty	66	52	14	26.9%
Total premiums	8,598	6,766	1,832	27.1%
Services	13	2	11	550%
Total premiums and services revenue	\$ 8,611	\$ 6,768	\$ 1,843	27.2%
Income before income taxes	\$ 329	\$ 418	\$ (89)	(21.3)%
Benefit ratio	84.7%	84.2%		0.5%

Operating cost ratio	11.4%	9.5%	1.9%
----------------------	-------	------	------

Table of Contents

	For the six months ended		Change	
	2014	June 30, 2013	Dollars (in millions)	Percentage
Premiums and Services Revenue:				
Premiums:				
Individual Medicare Advantage	\$ 12,935	\$ 11,308	\$ 1,627	14.4%
Medicare stand-alone PDP	1,802	1,546	256	16.6%
Total Retail Medicare	14,737	12,854	1,883	14.6%
Individual commercial	1,437	564	873	154.8%
State-based Medicaid	375	151	224	148.3%
Individual specialty	125	101	24	23.8%
Total premiums	16,674	13,670	3,004	22.0%
Services	27	4	23	575%
Total premiums and services revenue	\$ 16,701	\$ 13,674	\$ 3,027	22.1%
Income before income taxes	\$ 591	\$ 768	\$ (177)	(23.0)%
Benefit ratio	85.0%	85.0%		%
Operating cost ratio	11.4%	9.2%		2.2%

Pretax Results

Retail segment pretax income was \$329 million in the 2014 quarter, a decrease of \$89 million, or 21.3%, compared to \$418 million in the 2013 quarter. Retail segment pretax income was \$591 million in the 2014 period, a decrease of \$177 million, or 23.0%, compared to \$768 million in the 2013 period. These decreases are primarily driven by higher operating cost ratios in the 2014 quarter and period as well as a higher benefit ratio in the 2014 quarter.

Enrollment

Individual Medicare Advantage membership increased 333,300 members, or 16.4%, from June 30, 2013 to June 30, 2014 reflecting net membership additions, particularly for our HMO offerings, for the 2014 plan year.

Medicare stand-alone PDP membership increased 660,500 members, or 20.5%, from June 30, 2013 to June 30, 2014 reflecting net membership additions, primarily for our Humana-Walmart plan offering, for the 2014 plan year.

Individual commercial medical membership increased 676,000 members, or 119.0%, from June 30, 2013 to June 30, 2014 primarily reflecting new sales, both on-exchange and off-exchange, of plans compliant with

the Health Care Reform Law.

State-based Medicaid membership increased 92,400 members, or 130.9%, from June 30, 2013 to June 30, 2014, primarily driven by the addition of our Kentucky Medicaid contract and Florida Long-Term Support Services contracts.

Individual specialty membership increased 217,800 members, or 21.5%, from June 30, 2013 to June 30, 2014 primarily driven by increased membership in dental and vision offerings.

Table of Contents*Premiums*

Retail segment premiums increased \$1.8 billion, or 27.1%, from the 2013 quarter to the 2014 quarter and increased \$3.0 billion, or 22.0% from the 2013 period to the 2014 period primarily due to a 16.2% and 15.9% increase for the quarter and period, respectively, in average individual Medicare Advantage membership as well as individual commercial medical membership growth, primarily on the health care exchanges, that more than offset the impact of sequestration. Individual Medicare Advantage per member premiums remained relatively flat in the 2014 quarter as compared to the 2013 quarter and decreased approximately 1.3% in the 2014 period compared to the 2013 period primarily reflecting the impact of sequestration which became effective April 1, 2013.

Benefits expense

The Retail segment benefit ratio increased 50 basis points from 84.2% in the 2013 quarter to 84.7% in the 2014 quarter and remained flat at 85.0% in the 2014 and 2013 periods. The increase in the 2014 quarter primarily was due to lower prior-period medical claims reserve development, higher specialty prescription drug costs associated with a new treatment for Hepatitis C, and the new health care exchange offerings in the 2014 quarter. New individual commercial medical members in plans compliant with the Health Care Reform Law generally are expected to carry a higher benefit ratio than our previously underwritten membership. These items were partially offset by returns on investments in clinical programs and the inclusion of the health insurance industry fee in the pricing of our products.

The Retail segment's pretax income for the 2014 quarter included the beneficial effect of \$42 million in favorable prior-period medical claims reserve development versus \$72 million in the 2013 quarter. The decrease in the 2014 quarter is primarily due to prior year claims reprocessing in the 2014 quarter attributable to retroactive adjustments from policy extensions mandated by the Health Care Reform Law and, to a lesser extent, improvements in claims processing and front end audits in 2014. For the 2014 period, the Retail segment's benefit expense included the beneficial effect of \$264 million in favorable prior-period medical claims reserve development versus \$250 million in the 2013 period. This favorable prior-period medical claims reserve development decreased the Retail segment benefit ratio by approximately 50 basis points in the 2014 quarter versus approximately 110 basis points in the 2013 quarter, and by approximately 160 basis points in the 2014 period versus approximately 180 basis points in the 2013 period.

Operating costs

The Retail segment operating cost ratio of 11.4% for the 2014 quarter increased 190 basis points from 9.5% for the 2013 quarter. The Retail segment operating cost ratio of 11.4% for the 2014 period increased 220 basis points from 9.2% for the 2013 period. These increases are primarily due to the non-deductible health insurance industry fee mandated by the Health Care Reform Law, investments in health care exchanges and new state-based contracts, and higher Medicare Advantage marketing and distribution costs, partially offset by scale efficiencies from Medicare Advantage and individual commercial medical membership growth.

Table of Contents**Employer Group Segment**

	June 30,		Change	
	2014	2013	Members	Percentage
Membership:				
Medical membership:				
Group Medicare Advantage	479,700	416,600	63,100	15.1%
Group Medicare stand-alone PDP	4,400	3,700	700	18.9%
Total group Medicare	484,100	420,300	63,800	15.2%
Fully-insured commercial group	1,210,100	1,196,100	14,000	1.2%
ASO	1,120,100	1,199,600	(79,500)	(6.6)%
Total group medical members	2,814,300	2,816,000	(1,700)	(0.1)%
Group specialty membership (a)	6,576,000	7,256,800	(680,800)	(9.4)%

- (a) Specialty products include dental, vision, and voluntary benefit products. Members included in these products may not be unique to each product since members have the ability to enroll in multiple products.

	For the three months ended		Change	
	June 30,		Dollars	Percentage
	2014	2013	(in millions)	
Premiums and Services Revenue:				
Premiums:				
Group Medicare Advantage	\$ 1,366	\$ 1,160	\$ 206	17.8%
Group Medicare stand-alone PDP	2	2		%
Total group Medicare	1,368	1,162	206	17.7%
Fully-insured commercial group	1,321	1,273	48	3.8%
Group specialty	275	275		%
Total premiums	2,964	2,710	254	9.4%
Services	87	87		%
Total premiums and services revenue	\$ 3,051	\$ 2,797	\$ 254	9.1%
Income before income taxes	\$ 89	\$ 134	\$ (45)	(33.6)%
Benefit ratio	83.4%	82.5%		0.9%
Operating cost ratio	16.0%	15.1%		0.9%

Table of Contents

	For the six months ended		Change	
	2014	June 30, 2013	Dollars (in millions)	Percentage
Premiums and Services Revenue:				
Premiums:				
Group Medicare Advantage	\$ 2,750	\$ 2,350	\$ 400	17.0%
Group Medicare stand-alone PDP	4	4		%
Total group Medicare	2,754	2,354	400	17.0%
Fully-insured commercial group	2,650	2,541	109	4.3%
Group specialty	550	550		%
Total premiums	5,954	5,445	509	9.3%
Services	173	175	(2)	(1.1)%
Total premiums and services revenue	\$ 6,127	\$ 5,620	\$ 507	9.0%
Income before income taxes	\$ 315	\$ 346	\$ (31)	(9.0)%
Benefit ratio	81.1%	81.0%		0.1%
Operating cost ratio	16.1%	15.2%		0.9%

Pretax Results

Employer Group segment pretax income decreased \$45 million, or 33.6%, to \$89 million in the 2014 quarter, and decreased \$31 million, or 9.0%, to \$315 million for the 2014 period primarily due to increases in both the benefit and operating cost ratios as described below.

Enrollment

Fully-insured group Medicare Advantage membership increased 63,100 members, or 15.1%, from June 30, 2013 to June 30, 2014 primarily due to the addition of a new large account.

Fully-insured commercial group medical membership remained relatively unchanged, increasing 14,000 members, or 1.2%, from June 30, 2013 to June 30, 2014 as an increase in small group business membership was generally offset by lower membership in large group accounts.

Group ASO commercial medical membership decreased 79,500 members, or 6.6%, from June 30, 2013 to June 30, 2014 primarily due to continued pricing discipline in a highly competitive environment for self-funded accounts.

Group specialty membership decreased 680,800 members, or 9.4%, from June 30, 2013 to June 30, 2014 primarily due to declines in dental and vision membership related to our planned discontinuance of certain unprofitable product distribution partnerships.

Premiums

Employer Group segment premiums increased \$254 million, or 9.4%, to \$3.0 billion for the 2014 quarter, and increased \$509 million, or 9.3%, to \$6.0 billion for the 2014 period primarily due to higher average group Medicare Advantage membership.

Table of Contents*Benefits expense*

The Employer Group segment benefit ratio increased 90 basis points from 82.5% in the 2013 quarter to 83.4% in the 2014 quarter, and increased 10 basis points from 81.0% in the 2013 period to 81.1% in the 2014 period. The increases are primarily due to lower favorable prior-period medical claims reserve development and higher specialty prescription drug costs associated with a new treatment for Hepatitis C, partially offset by the inclusion of the health insurance industry fee and other fees mandated by the Health Care Reform Law in our pricing. The Employer Group segment's pretax income for the 2014 quarter included the beneficial effect of \$9 million in favorable prior-period medical claims reserve development versus \$27 million in the 2013 quarter. The decline in favorable prior-period medical claims reserve development primarily reflects higher 2013 claims severity for our fully-insured commercial group business and, to a lesser extent, improvements in claims processing and front end audits in 2014. For the 2014 period, the Employer Group segment's pretax income included the beneficial effect of \$83 million in favorable prior-period medical claims reserve development versus \$113 million in the 2013 period. This favorable prior-period medical claims reserve development decreased the Employer Group segment benefit ratio by approximately 30 basis points in the 2014 quarter versus approximately 100 basis points in the 2013 quarter, and by approximately 140 basis points in the 2014 period versus 210 basis points in the 2013 period.

Operating costs

The Employer Group segment operating cost ratio of 16.0% for the 2014 quarter increased 90 basis points from 15.1% for the 2013 quarter. For the 2014 period, the Employer Group segment operating cost ratio of 16.1% increased 90 basis points from 15.2% for the 2013 period. The increases primarily reflect the impact of the non-deductible health insurance industry fee and other fees mandated by the Health Care Reform Law, partially offset by an increase in group Medicare Advantage membership which generally carries a lower operating cost ratio than our commercial group medical membership.

Healthcare Services Segment

	For the three months ended		Change	
	2014	2013	Dollars	Percentage
	(in millions)			
Revenues:				
Services:				
Provider services	\$ 282	\$ 289	\$ (7)	(2.4)%
Home based services	25	23	2	8.7%
Pharmacy solutions	25	13	12	92.3%
Total services revenues	332	325	7	2.2%
Intersegment revenues:				
Pharmacy solutions	4,204	3,212	992	30.9%
Provider services	260	271	(11)	(4.1)%

Edgar Filing: HUMANA INC - Form 10-Q

Home based services	138	72	66	91.7%
Integrated behavioral health services	33	31	2	6.5%
Total intersegment revenues	4,635	3,586	1,049	29.3%
Total services and intersegment revenues	\$ 4,967	\$ 3,911	\$ 1,056	27.0%
Income before income taxes	\$ 206	\$ 124	\$ 82	66.1%
Operating cost ratio	95.1%	95.9%		(0.8)%

Table of Contents

	For the six months ended		Change Dollars	Change Percentage
	2014	June 30, 2013		
Revenues:				
Services:				
Provider services	\$ 549	\$ 571	\$ (22)	(3.9)%
Home based services	48	46	2	4.3%
Pharmacy solutions	46	22	24	109.1%
Integrated behavioral health services		1	(1)	(100.0)%
Total services revenues	643	640	3	0.5%
Intersegment revenues:				
Pharmacy solutions	8,061	6,297	1,764	28.0%
Provider services	552	550	2	0.4%
Home based services	256	132	124	93.9%
Integrated behavioral health services	66	62	4	6.5%
Total intersegment revenues	8,935	7,041	1,894	26.9%
Total services and intersegment revenues	\$ 9,578	\$ 7,681	\$ 1,897	24.7%
Income before income taxes	\$ 391	\$ 242	\$ 149	61.6%
Operating cost ratio	95.2%	95.9%		(0.7)%

Pretax results

Healthcare Services segment pretax income of \$206 million for the 2014 quarter increased \$82 million, or 66.1%, from \$124 million for the 2013 quarter. For the 2014 period, the Healthcare Services segment pretax income of \$391 million increased \$149 million, or 61.6%, from \$242 million for the 2013 period. These increases are primarily due to revenue growth and pretax income contribution from our pharmacy solutions and home based services businesses as they serve our growing medical membership.

Script Volume

Humana Pharmacy Solutions® script volumes for Retail and Employer Group segment membership increased to approximately 82 million in the 2014 quarter, up 20% versus scripts of approximately 68 million in the 2013 quarter. For the 2014 period, script volumes for Retail and Employer Group segment membership increased to approximately 160 million, up 19% versus scripts of approximately 134 million in the 2013 period. These increases primarily reflect growth associated with higher average medical membership for the 2014 quarter and period than in the 2013 quarter and period.

Services revenue

Edgar Filing: HUMANA INC - Form 10-Q

Services revenue for the 2014 quarter and period were relatively unchanged from the 2013 quarter and period, increasing \$7 million, or 2.2%, and \$3 million, or 0.5%, respectively.

Table of Contents*Intersegment revenues*

Intersegment revenues increased \$1.0 billion, or 29.3%, from the 2013 quarter to \$4.6 billion for the 2014 quarter and increased \$1.9 billion, or 26.9%, from the 2013 period to \$8.9 billion primarily due to growth in our pharmacy solutions and home based services businesses as they serve our growing medical membership.

Operating costs

The Healthcare Services segment operating cost ratio of 95.1% for the 2014 quarter decreased 80 basis points from 95.9% for the 2013 quarter. The Healthcare Services segment operating ratio of 95.2% for the 2014 period decreased 70 basis points from 95.9% for the 2013 period. The decreases are primarily due to scale efficiencies associated with growth in our pharmacy solutions business.

Other Businesses

Pretax income for our Other Businesses of \$17 million for the 2014 quarter increased \$47 million compared to a pretax loss of \$30 million for the 2013 quarter. For the 2014 period, pretax income of \$42 million increased \$14 million compared to pretax income of \$28 million in the 2013 period. These increases primarily were due to costs in the 2013 quarter and period associated with the loss of our Medicaid contracts in Puerto Rico, as discussed previously, partially offset by a reduction in benefits expense in the 2013 period related to a favorable settlement of contract claims with the DoD associated with previously disclosed litigation.

Liquidity

Our primary sources of cash include receipts of premiums, services revenue, and investment and other income, as well as proceeds from the sale or maturity of our investment securities and borrowings. Our primary uses of cash include disbursements for claims payments, operating costs, interest on borrowings, taxes, purchases of investment securities, acquisitions, capital expenditures, repayments on borrowings, dividends, and share repurchases. Because premiums generally are collected in advance of claim payments by a period of up to several months, our business normally should produce positive cash flows during periods of increasing premiums and enrollment. Conversely, cash flows would be negatively impacted during periods of decreasing premiums and enrollment. From period to period, our cash flows may also be affected by the timing of working capital items including taxes and assessments. The use of operating cash flows may be limited by regulatory requirements which require, among other items, that our regulated subsidiaries maintain minimum levels of capital and seek approval before paying dividends from the subsidiaries to the parent. Our use of operating cash flows derived from our non-insurance subsidiaries, such as in our Healthcare Services segment, is generally not restricted by Departments of Insurance.

For 2014, the effect of the commercial risk adjustment, risk corridor, and reinsurance provisions of the Health Care Reform Law are impacting the timing of our operating cash flows, as we expect to build a receivable in 2014 that will be collected in 2015. It is reasonably possible that the receivable could be material to our operating cash flow for the full year 2014. For the full year 2014, we expect our operating cash flows to decline from 2013. In addition, we expect our 2014 financing cash flows to be negatively impacted by the timing of payments to and receipts from CMS associated with Medicare Part D reinsurance subsidies for which we do not assume risk. We are experiencing higher specialty prescription drug costs associated with a new treatment for Hepatitis C than were contemplated in our bids which is resulting in higher reinsurance subsidy receivable balances in 2014 that will be settled in 2015 under the terms of our contracts with CMS. Any amounts receivable or payable associated with these risk limiting programs and

CMS subsidies may have an impact on subsidiary liquidity, with any temporary shortfalls funded by the parent company.

For additional information on our liquidity risk, please refer to the section entitled **Risk Factors** in this report and in our 2013 Form 10-K.

Table of Contents

Cash and cash equivalents increased to \$1.6 billion at June 30, 2014 from \$1.1 billion at December 31, 2013. The change in cash and cash equivalents for the six months ended June 30, 2014 and 2013 is summarized as follows:

	2014	2013
	(in millions)	
Net cash provided by operating activities	\$ 471	\$ 585
Net cash provided by (used in) investing activities	404	(148)
Net cash used in financing activities	(420)	(224)
 Increase in cash and cash equivalents	 \$ 455	 \$ 213

Cash Flow from Operating Activities

The decrease in operating cash flows from the 2013 period to the 2014 period primarily results from lower earnings and the timing of working capital items. The most significant drivers of changes in our working capital are typically the timing of payments of benefits expense and receipts for premiums. We illustrate these changes with the following summaries of benefits payable and receivables.

The detail of benefits payable was as follows at June 30, 2014 and December 31, 2013:

	June 30,	December 31,	2014	2013
	2014	2013	Period	Period
	(in millions)			
IBNR (1)	\$ 3,242	\$ 2,586	\$ 656	\$ 215
Reported claims in process (2)	635	381	254	168
Other benefits payable (3)	901	926	(25)	(5)
 Total benefits payable	 \$ 4,778	 \$ 3,893	 \$ 885	 \$ 378

- (1) IBNR represents an estimate of benefits payable for claims incurred but not reported (IBNR) at the balance sheet date. The level of IBNR is primarily impacted by membership levels, medical claim trends and the receipt cycle time, which represents the length of time between when a claim is initially incurred and when the claim form is received (i.e. a shorter time span results in a lower IBNR).
- (2) Reported claims in process represents the estimated valuation of processed claims that are in the post claim adjudication process, which consists of administrative functions such as audit and check batching and handling, as well as amounts owed to our pharmacy benefit administrator which fluctuate due to bi-weekly payments and the month-end cutoff.
- (3) Other benefits payable primarily include amounts owed to providers under capitated and risk sharing arrangements.

The increase in benefits payable from December 31, 2013 to June 30, 2014 primarily was due to an increase in IBNR, primarily as a result of Medicare Advantage membership growth, and an increase in the amount of processed but

unpaid claims, including amounts due to our pharmacy benefit administrator, which fluctuate due to month-end cutoff. The increase in benefits payable from December 31, 2012 to June 30, 2013 primarily was due to the same factors resulting in the increase in benefits payable from December 31, 2013 to June 30, 2014 described above.

Table of Contents

The detail of total net receivables was as follows at June 30, 2014 and December 31, 2013:

	June 30, 2014	December 31, 2013	2014 Period Change	2013 Period Change
	(in millions)			
Medicare	\$ 1,681	\$ 576	\$ 1,105	\$ 786
Commercial and other	418	405	13	42
Military services	96	87	9	47
Allowance for doubtful accounts	(121)	(118)	(3)	(15)
Total net receivables	\$ 2,074	\$ 950	1,124	860
Reconciliation to cash flow statement:				
Disposition of receivables from sale of business			13	
Change in receivables per cash flow statement resulting in cash from operations			\$ 1,137	\$ 860

The increases in Medicare receivables reflect the typical pattern caused by the timing of accruals and related collections associated with the CMS risk-adjustment model. Significant collections occur with the final and mid-year settlements with CMS in July and August, respectively. In connection with our July 2014 payment from CMS, we collected \$558 million associated with the final Medicare risk-adjustment payment for the 2013 plan year. In addition, in connection with our August 2014 payment from CMS, we expect to collect \$794 million associated with the mid-year Medicare risk-adjustment payment.

Military services receivables at June 30, 2014 and December 31, 2013 primarily consist of administrative services only fees owed from the federal government for administrative services provided under our TRICARE South Region contract and final settlement balances due under our previous TRICARE South Region contract. Payments of the federal government's claims and related reimbursements under our current TRICARE South Region contract are classified with receipts (withdrawals) from contract deposits as a financing item in our consolidated statements of cash flows.

Many provisions of the Health Care Reform Law became effective in 2014, including the commercial risk adjustment, risk corridor, and reinsurance provisions as well as the non-deductible health insurance industry fee. As discussed previously, the timing of payments and receipts associated with these provisions will impact our operating cash flows as we expect to build a receivable in 2014 that will be collected in 2015. The net receivable balance associated with the 3Rs was approximately \$240 million at June 30, 2014.

In addition to the timing of receipts for premiums and services revenues, payments of benefits expense, and amounts due under the risk limiting and health insurance industry fee provisions of the Health Care Reform Law, other working capital items impacting operating cash flows primarily resulted from the timing of payments for the Medicare Part D risk corridor provisions of our contracts with CMS and changes in the timing of the collection of pharmacy rebates.

Cash Flow from Investing Activities

Proceeds from sales and maturities of investment securities exceeded purchases by \$551 million in the 2014 period. These net proceeds were used to fund normal working capital needs due to the typical pattern caused by the timing of accruals and related collections associated with the CMS risk-adjustment model coupled with an increase in receivables in 2014 that will be collected in 2015 associated with the commercial risk adjustment, risk corridor, and reinsurance provisions of the Health Care Reform Law in addition to the timing of payments to and receipts from CMS associated with Medicare Part D reinsurance subsidies, as discussed previously. In the 2013 period we reinvested a portion of our operating cash flows in investment securities, primarily investment-grade fixed income securities, totaling \$18 million.

Our ongoing capital expenditures primarily relate to our information technology initiatives, support of services in our provider services operations including medical and administrative facility improvements necessary for activities such as the provision of care to members, claims processing, billing and collections, wellness solutions, care coordination,

Table of Contents

regulatory compliance and customer service. Total capital expenditures, excluding acquisitions, were \$216 million in the 2014 period and \$187 million in the 2013 period reflecting increased spending associated with growth in our provider services and pharmacy businesses in our Healthcare Services segment. Excluding acquisitions, we expect total capital expenditures in 2014 in a range of approximately \$525 million to \$575 million.

Cash Flow from Financing Activities

Claims payments were \$122 million higher than receipts from CMS associated with Medicare Part D claim subsidies for which we do not assume risk during the 2014 period. During the 2013 period, receipts from CMS associated with Medicare Part D claim subsidies for which we do not assume risk were \$144 million higher than claims payments. As discussed previously, we expect our 2014 financing cash flows to be negatively impacted by the timing of payments to and receipts from CMS associated with Medicare Part D claim subsidies for which we do not assume risk. We are experiencing higher specialty prescription drug costs associated with a new treatment for Hepatitis C than were contemplated in our bids which is resulting in higher subsidy receivable balances in 2014 that will be settled in 2015 under the terms of our contracts with CMS. Our net receivable for CMS subsidies and brand name prescription drug discounts was \$835 million at June 30, 2014 compared to \$414 million at June 30, 2013 and \$713 million at December 31, 2013. Refer to Note 6 to the condensed consolidated financial statements.

Under our administrative services only TRICARE South Region contract, health care cost payments for which we do not assume risk exceeded reimbursements from the federal government by \$29 million during the 2014 period compared to \$12 million during the 2013 period.

Receipts from HHS associated with cost sharing provisions of the Health Care Reform Law for which we do not assume risk were \$24 million higher than claims payments.

We repurchased 0.91 million shares for \$112 million in the 2014 period and 2.83 million shares for \$211 million in the 2013 period under share repurchase plans authorized by the Board of Directors. We also acquired common shares in connection with employee stock plans for an aggregate cost of \$40 million in the 2014 period and \$20 million in the 2013 period.

During the 2014 period we paid dividends to stockholders of \$86 million as compared to \$83 million in the 2013 period, as discussed further below.

Future Sources and Uses of Liquidity**Dividends**

The following table provides details of dividend payments in 2013 and 2014 under our Board approved quarterly cash dividend policy:

Record Date	Payment Date	Amount per Share	Total Amount (in millions)
2013 payments			
12/31/2012	1/25/2013	\$ 0.26	\$ 42
3/28/2013	4/26/2013	\$ 0.26	\$ 41

Edgar Filing: HUMANA INC - Form 10-Q

6/28/2013	7/26/2013	\$ 0.27	\$ 42
9/30/2013	10/25/2013	\$ 0.27	\$ 42
2014 payments			
12/31/2013	1/31/2014	\$ 0.27	\$ 42
3/31/2014	4/25/2014	\$ 0.27	\$ 42
6/30/2014	7/25/2014	\$ 0.28	\$ 43

Table of Contents

Declaration and payment of future quarterly dividends is at the discretion of the Board and may be adjusted as business needs or market conditions change.

Stock Repurchases

In April 2014, the Board of Directors replaced a previous share repurchase authorization of up to \$1 billion (of which \$569 million remained unused) with a new authorization for repurchases of up to \$1 billion of our common shares exclusive of shares repurchased in connection with employee stock plans, expiring on June 30, 2016. Under the new share repurchase authorization, shares may be purchased from time to time at prevailing prices in the open market, by block purchases, or in privately-negotiated transactions, subject to certain regulatory restrictions on volume, pricing, and timing. During the six months ended June 30, 2014, we repurchased 0.1 million shares in open market transactions for \$11 million at an average price of \$113.44 under a previous share repurchase authorization and we repurchased 0.81 million shares in open market transactions for \$101 million at an average price of \$125.04 under the current authorization. During the six months ended June 30, 2013, we repurchased 2.83 million shares in open market transactions for \$211 million at an average price of \$74.67 under previous share repurchase authorizations. As of July 30, 2014, the remaining authorized amount under the new authorization totaled \$899 million.

In connection with employee stock plans, we acquired 0.4 million common shares for \$40 million and 0.2 million common shares for \$20 million during the six months ended June 30, 2014 and 2013, respectively.

Senior Notes

We previously issued \$500 million of 6.45% senior notes due June 1, 2016, \$500 million of 7.20% senior notes due June 15, 2018, \$300 million of 6.30% senior notes due August 1, 2018, \$600 million of 3.15% senior notes due December 1, 2022, \$250 million of 8.15% senior notes due June 15, 2038, and \$400 million of 4.625% senior notes due December 1, 2042. The 7.20% and 8.15% senior notes are subject to an interest rate adjustment if the debt ratings assigned to the notes are downgraded (or subsequently upgraded). In addition, our 7.20%, 8.15%, 3.15%, and 4.625% senior notes contain a change of control provision that may require us to purchase the notes under certain circumstances. All six series of our senior notes, which are unsecured, may be redeemed at our option at any time at 100% of the principal amount plus accrued interest and a specified make-whole amount.

Credit Agreement

In July 2013, we amended and restated our 5-year \$1.0 billion unsecured revolving credit agreement to, among other things, extend its maturity to July 2018 from November 2016. Under the amended and restated credit agreement, at our option, we can borrow on either a competitive advance basis or a revolving credit basis. The revolving credit portion bears interest at either LIBOR plus a spread or the base rate plus a spread. The LIBOR spread, currently 110 basis points, varies depending on our credit ratings ranging from 90.0 to 150.0 basis points. We also pay an annual facility fee regardless of utilization. This facility fee, currently 15.0 basis points, may fluctuate between 10.0 and 25.0 basis points, depending upon our credit ratings. The competitive advance portion of any borrowings will bear interest at market rates prevailing at the time of borrowing on either a fixed rate or a floating rate based on LIBOR, at our option.

The terms of the credit agreement include standard provisions related to conditions of borrowing, including a customary material adverse effect clause which could limit our ability to borrow additional funds. In addition, the credit agreement contains customary restrictive and financial covenants as well as customary events of default, including financial covenants regarding the maintenance of a minimum level of net worth of \$7.6 billion at June 30, 2014 and a maximum leverage ratio of 3.0:1. We are in compliance with the financial covenants, with actual net worth

of \$10.0 billion and actual leverage ratio of 1.0:1, as measured in accordance with the credit agreement as of June 30, 2014. In addition, the credit agreement includes an uncommitted \$250 million incremental loan facility.

At June 30, 2014, we had no borrowings outstanding under the credit agreement. We have outstanding letters of credit of \$5 million secured under the credit agreement. No amounts have been drawn on these letters of credit. Accordingly, as of June 30, 2014, we had \$995 million of remaining borrowing capacity under the credit agreement, none of which would be restricted by our financial covenant compliance requirement. We have other customary, arms-length relationships, including financial advisory and banking relationships, with some parties to the credit agreement.

Table of Contents***Liquidity Requirements***

We believe our cash balances, investment securities, operating cash flows, and funds available under our credit agreement or from other public or private financing sources, taken together, provide adequate resources to fund ongoing operating and regulatory requirements, acquisitions, future expansion opportunities, and capital expenditures for at least the next twelve months, as well as to refinance or repay debt, and repurchase shares.

Adverse changes in our credit rating may increase the rate of interest we pay and may impact the amount of credit available to us in the future. Our investment-grade credit rating at June 30, 2014 was BBB+ according to Standard & Poor's Rating Services, or S&P, and Baa3 according to Moody's Investors Services, Inc., or Moody's. A downgrade by S&P to BB+ or by Moody's to Ba1 triggers an interest rate increase of 25 basis points with respect to \$750 million of our senior notes. Successive one notch downgrades increase the interest rate an additional 25 basis points, or annual interest expense by \$2 million, up to a maximum 100 basis points, or annual interest expense by \$8 million.

In addition, we operate as a holding company in a highly regulated industry. Humana Inc., our parent company, is dependent upon dividends and administrative expense reimbursements from our subsidiaries, most of which are subject to regulatory restrictions. We continue to maintain significant levels of aggregate excess statutory capital and surplus in our state-regulated operating subsidiaries. Cash, cash equivalents, and short-term investments at the parent company were \$736 million at June 30, 2014 compared to \$508 million at December 31, 2013. As described in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations under the section titled Health Care Reform, statutory accounting for the health insurance industry fee requires us to restrict surplus in the year preceding payment beginning in 2014. Therefore, in addition to recording the full-year 2014 assessment in the first quarter of 2014, we are required to restrict surplus for the 2015 assessment ratably in 2014. In 2014, we expect to pay the federal government approximately \$560 million for the annual health insurance industry fee. In 2015, the health insurance industry fee increases by 41% for the industry taken as a whole. Accordingly, absent changes in market share, we would expect a similar increase in our fee in 2015.

Regulatory Requirements

Certain of our subsidiaries operate in states that regulate the payment of dividends, loans, or other cash transfers to Humana Inc., our parent company, and require minimum levels of equity as well as limit investments to approved securities. The amount of dividends that may be paid to Humana Inc. by these subsidiaries, without prior approval by state regulatory authorities, or ordinary dividends, is limited based on the entity's level of statutory income and statutory capital and surplus. In most states, prior notification is provided before paying a dividend even if approval is not required. Actual dividends paid may vary due to consideration of excess statutory capital and surplus and expected future surplus requirements related to, for example, premium volume and product mix.

Although minimum required levels of equity are largely based on premium volume, product mix, and the quality of assets held, minimum requirements vary significantly at the state level. Based on the most recently filed statutory financial statements as of March 31, 2014, our state regulated subsidiaries had aggregate statutory capital and surplus of approximately \$5.5 billion, which exceeded aggregate minimum regulatory requirements of \$3.6 billion. The amount of dividends that were paid to our parent company in the 2014 period was approximately \$695 million in the aggregate. In addition, \$219 million of dividends were paid to our parent company in July 2014, bringing the full year total through July 30, 2014 to \$914 million. This compares to dividends that were paid for the full year 2013 of approximately \$967 million. The year-over-year decline is a result of higher surplus requirements associated with premium growth due to increases in membership.

Table of Contents**Item 3. Quantitative and Qualitative Disclosures about Market Risk**

Our earnings and financial position are exposed to financial market risk, including those resulting from changes in interest rates.

Interest rate risk also represents a market risk factor affecting our consolidated financial position due to our significant investment portfolio, consisting primarily of fixed maturity securities of investment-grade quality with a weighted average S&P credit rating of AA- at June 30, 2014. Our net unrealized position increased \$251 million from a net unrealized gain position of \$250 million at December 31, 2013 to a net unrealized gain position of \$501 million at June 30, 2014. At June 30, 2014, we had gross unrealized losses of \$43 million on our investment portfolio primarily due to an increase in market interest rates and tighter liquidity conditions in the current markets than when the securities were purchased. There were no material other-than-temporary impairments during the three months ended June 30, 2014. While we believe that these impairments are temporary and we currently do not have the intent to sell such securities, given the current market conditions and the significant judgments involved, there is a continuing risk that future declines in fair value may occur and material realized losses from sales or other-than-temporary impairments may be recorded in future periods.

Duration is the time-weighted average of the present value of the bond portfolio's cash flow. Duration is indicative of the relationship between changes in fair value and changes in interest rates, providing a general indication of the sensitivity of the fair values of our fixed maturity securities to changes in interest rates. However, actual fair values may differ significantly from estimates based on duration. The average duration of our investment portfolio, including cash and cash equivalents, was approximately 4.4 years as of June 30, 2014 and 4.3 years as of December 31, 2013. Based on the duration, including cash equivalents, a 1% increase in interest rates would generally decrease the fair value of our securities by approximately \$471 million.

Item 4. Controls and Procedures

Under the supervision and with the participation of our Chief Executive Officer, or CEO, our Chief Financial Officer, or CFO, and our Principal Accounting Officer, we carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures for the quarter ended June 30, 2014.

Based on our evaluation, our CEO, CFO, and our Principal Accounting Officer concluded that our disclosure controls and procedures are effective to provide reasonable assurance that information the Company is required to disclose in its reports under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, including, without limitation, ensuring that such information is accumulated and communicated to the Company's management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

There have been no changes in the Company's internal control over financial reporting during the quarter ended June 30, 2014 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

Table of Contents**Part II. Other Information****Item 1. Legal Proceedings**

For a description of the legal proceedings pending against us and certain other pending or threatened litigation, investigations, or other matters, see **Legal Proceedings and Certain Regulatory Matters** in Note 11 to the condensed consolidated financial statements beginning on page 21 of this Form 10-Q.

Item 1A. Risk Factors

Except as set forth below, there have been no changes to the risk factors included in our 2013 Form 10-K. The following replaces in its entirety the fourth bullet under the risk factor in our 2013 Form 10-K entitled, *As a government contractor, we are exposed to risks that may materially adversely affect our business or our willingness or ability to participate in government health care programs.*

CMS uses a risk-adjustment model which apportions premiums paid to Medicare Advantage, or MA, plans according to health severity. The risk-adjustment model pays more for enrollees with predictably higher costs. Under this model, rates paid to MA plans are based on actuarially determined bids, which include a process that bases our prospective payments on a comparison of our beneficiaries' risk scores, derived from medical diagnoses, to those enrolled in the government's traditional fee-for-service Medicare program (referred to as Medicare FFS). Under the risk-adjustment methodology, all MA plans must collect and submit the necessary diagnosis code information from hospital inpatient, hospital outpatient, and physician providers to CMS within prescribed deadlines. The CMS risk-adjustment model uses this diagnosis data to calculate the risk-adjusted premium payment to MA plans. We generally rely on providers, including certain providers in our network who are our employees, to code their claim submissions with appropriate diagnoses, which we send to CMS as the basis for our payment received from CMS under the actuarial risk-adjustment model. We also rely on providers to appropriately document all medical data, including the diagnosis data submitted with claims. In addition, we conduct medical record reviews as part of our data and payment accuracy compliance efforts, to more accurately reflect diagnosis conditions under the risk adjustment model.

These compliance efforts include the internal contract level audits described in more detail below.

CMS is continuing to perform audits of various companies' selected MA contracts related to this risk adjustment diagnosis data. These audits are referred to herein as Risk-Adjustment Data Validation Audits, or RADV audits. RADV audits review medical records in an attempt to validate provider medical record documentation and coding practices which influence the calculation of premium payments to MA plans.

On February 24, 2012, CMS released a **Notice of Final Payment Error Calculation Methodology for Part C Medicare Advantage Risk Adjustment Data Validation (RADV) Contract-Level Audits**. The final payment error calculation methodology provides that, in calculating the economic impact of audit results for an MA contract, if any, the results of the audit sample will be extrapolated to the entire MA contract based upon a comparison to benchmark audit data in Medicare FFS (which we refer to as the FFS Adjuster). This comparison to a Medicare FFS benchmark audit is necessary to determine the economic impact, if any, of audit results because the government program data set, including any attendant errors that are present in that data set, provides the basis for MA plans' risk adjustment to payment rates.

The final methodology, including the first application of extrapolated audit results to determine audit settlements, is expected to be applied to the next round of RADV contract level audits to be conducted on 2011 premium payments. Selected MA contracts will be notified of an audit at some point after the close of the final reconciliation for the payment year being audited. The final reconciliation occurs in August of the calendar year following the payment year. We have been notified that certain of our Medicare Advantage contracts have been selected for audit for contract year 2011.

Table of Contents

Estimated audit settlements are recorded as a reduction of premiums revenue in our consolidated statements of income, based upon available information. During 2012, we completed internal contract level audits of certain 2011 contracts based on the RADV audit methodology prescribed by CMS. Included in these internal contract level audits was an audit of our Private Fee-For-Service business which we used to represent a proxy of the benchmark audit data in Medicare FFS which has not yet been released. We based our accrual of estimated audit settlements for contract years 2011 (the first year that application of extrapolated audit results is applicable) and 2012 on the results of these internal contract level audits for contract year 2011. Estimates derived from these results were not material to our results of operations, financial position, or cash flows. However, as indicated, we are awaiting additional guidance from CMS regarding the benchmark audit data in Medicare FFS. Accordingly, we cannot determine whether such audits will have a material adverse effect on our results of operations, financial position, or cash flows.

In addition, CMS' recent comments in formalized guidance regarding overpayments to Medicare Advantage plans appear to be inconsistent with the Agency's prior RADV audit guidance. These statements, contained in the preamble to CMS' final rule release regarding Medicare Advantage and Part D prescription drug benefit program regulations for Contract Year 2015, appear to equate each Medicare Advantage risk adjustment data error with an overpayment without reconciliation to the principles underlying the FFS Adjuster referenced above. We will continue to work with CMS to ensure that Medicare Advantage plans are paid accurately and that payment model principles are in accordance with the requirements of the Social Security Act, which if not implemented correctly, could have material adverse effect on our results of operations, financial position, or cash flows.

Item 2: Unregistered Sales of Equity Securities and Use of Proceeds

- (a) None.
- (b) N/A
- (c) The following table provides information about purchases by us during the three months ended June 30, 2014 of equity securities that are registered by us pursuant to Section 12 of the Exchange Act:

Period	Total Number of Shares Purchased (1)	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (1)(2)	Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (1)
April 2014				\$ 1,000,000,000
May 2014				1,000,000,000
June 2014	805,483	125.04	805,483	899,310,474

Total	805,483	\$ 125.04	805,483	899,310,474
-------	---------	-----------	---------	-------------

- (1) As announced on May 7, 2014, in April 2014, the Board of Directors replaced a previous share repurchase authorization of up to \$1 billion with a new authorization for repurchases of up to \$1 billion of our common shares exclusive of shares repurchased in connection with employee stock plans, expiring on June 30, 2016. Under the new share repurchase authorization, shares may be purchased from time to time at prevailing prices in the open market, by block purchases, or in privately-negotiated transactions, subject to certain regulatory restrictions on volume, pricing, and timing. As of July 30, 2014, the remaining authorized amount under the current authorization totaled \$899 million.
- (2) Excludes 0.4 million shares repurchased in connection with employee stock plans.

Table of Contents

Item 3: Defaults Upon Senior Securities

None.

Item 4: Mine Safety Disclosures

Not applicable.

Item 5: Other Information

None.

Item 6: Exhibits

- 3(i) Restated Certificate of Incorporation of Humana Inc. filed with the Secretary of State of Delaware on November 9, 1989, as restated to incorporate the amendment of January 9, 1992, and the correction of March 23, 1992 (incorporated herein by reference to Exhibit 4(i) to Humana Inc.'s Post-Effective Amendment No. 1 to the Registration Statement on Form S-8 (Reg. No. 33-49305) filed February 2, 1994).
- 3(ii) By-Laws of Humana Inc., as amended on January 4, 2007 (incorporated herein by reference to Exhibit 3 to Humana Inc.'s Annual Report on Form 10-K for the year ended December 31, 2006).
- 12 Computation of ratio of earnings to fixed charges.
- 31.1 Principal Executive Officer certification pursuant to Section 302 of Sarbanes Oxley Act of 2002.
- 31.2 Principal Financial Officer certification pursuant to Section 302 of Sarbanes Oxley Act of 2002.
- 32 Principal Executive Officer and Principal Financial Officer certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
- 101 The following materials from Humana Inc.'s Quarterly Report of Form 10-Q formatted in XBRL (Extensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets at June 30, 2014 and December 31, 2013; (ii) the Condensed Consolidated Statements of Income for the three and six months ended June 30, 2014 and 2013; (iii) the Condensed Consolidated Statements of Comprehensive Income for the three and six months ended June 30, 2014 and 2013; (iv) the Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2014 and 2013; and (v) Notes to Condensed Consolidated Financial Statements.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

HUMANA INC.

(Registrant)

Date: July 30, 2014

By: /s/ STEVEN E. McCULLEY
Steven E. McCulley
Senior Vice President and Chief Accounting Officer
(Principal Accounting Officer and Duly
Authorized Officer)